order to obtain a polynucleotide derivative that is stable in cells, a base, a sugar, and a phosphoric acid portion may chemically be modified. Examples of the aforementioned polynucleotide synthesis method may include the phosphate triester method, the phosphoramidite method, and the H-phosphorate method.

A polynucleotide wherein guanosine is methylated at position 6 may be produced using the following compound as a starting material, for example:

(Pharmaceutical composition for preventing or treating immune-mediated diseases)

As described later in test examples of the present specification, it has been confirmed that the polynucleotide of the present invention comprising a CpG motif wherein guanine is methylated can suppress the generation of interleukin when a mouse bone marrow-derived macrophage is stimulated with CpG DNA or the like, and that it can also suppresses arthritis in type II collagen arthritis model mice. That is to say, the present invention provides a pharmaceutical composition comprising, as an active ingredient, a polynucleotide having a CpG motif wherein guanine is methylated. The pharmaceutical composition of the present invention has action to suppress immunity, and thus, it can be used for preventing and/or treating immune-mediated diseases. The pharmaceutical composition of the present invention can be used for preventing and/or treating autoimmune diseases such as articular rheumatism, systemic lupus crythematosus,

# STRUCTURE SEARCH-PT.I

#### => FILE REG

FILE 'REGISTRY' ENTERED AT 17:33:28 ON 19 APR 2010 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8 DICTIONARY FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8


New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html




chain nodes :
15
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14
chain bonds :
2-15 9-10
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

#### Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

Uploading LL15.str



chain nodes:
10 17 18 19
ring nodes:
1 2 3 4 5 6 7 8 9 11 12 13 14 15
chain bonds:
2-17 4-10 9-11 10-19 17-18
ring bonds:
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 11-12 11-15 12-13 13-14 14-15
exact/norm bonds:
1-2 1-6 2-3 2-17 3-4 4-5 4-10 5-6 5-7 6-9 7-8 8-9 9-11 10-19 11-12
11-15 12-13 13-14 14-15 17-18

G1:n-Bu,i-Bu,s-Bu,t-Bu

#### Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 19:CLASS

#### => FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 17:33:32 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2010 VOL 152 ISS 17

FILE LAST UPDATED: 18 Apr 2010 (20100418/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.


CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

#### => D STAT QUE L20

L8 STR



NODE A	TTRIE	BUTE	S:		
NSPEC	IS	R		ΑT	1
NSPEC	IS	R		ΑT	2
NSPEC	IS	R		ΑT	3
NSPEC	IS	R		ΑT	4
NSPEC	IS	R		ΑT	5
NSPEC	IS	R		ΑT	6

#### **Page 5 of 58**

NSPEC	IS R	AT	./	
NSPEC	IS R	AT	8	
NSPEC	IS R	AT	9	
NSPEC	IS R	AT	10	
NSPEC	IS R	AT	11	
NSPEC	IS R	AT	12	
NSPEC	IS R	AT	13	
NSPEC	IS R	AT	14	
NSPEC	IS C	AT	15	
DEFAULT	MLEVEL	IS ATO	M	
MLEVEL	IS CLAS	S AT	15	
DEFAULT	ECLEVEL	IS LI	MITED	


#### GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

L10 67307 SEA FILE=REGISTRY SSS FUL L8


L15 STR



Page 1-A

8

Page 1-B



# Serial#: 10/553,948 Page 2-A VAR G1=19/23/27/31 NODE ATTRIBUTES: HCOUNT IS M2 AT 19 HCOUNT IS M2 AT 19 HCOUNT IS E2 AT 20 HCOUNT IS E2 AT 21 HCOUNT IS E3 AT 22 HCOUNT IS E1 AT 24 HCOUNT IS E3 AT 25 HCOUNT IS E3 AT 26 HCOUNT IS E3 AT 27 HCOUNT IS E3 AT 28 HCOUNT IS E3 AT 29 HCOUNT IS E3 AT 30 HCOUNT IS E3 AT 32 HCOUNT IS E3 AT 33 HCOUNT IS E3 AT 34 NSPEC IS R AT 1 NSPEC IS R AT 2 NSPEC IS R <td HCOUNT IS E2 AT 20 DEFAULT MLEVEL IS ATOM MLEVEL IS CLASS AT 10 16 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 DEFAULT ECLEVEL IS LIMITED GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 34 STEREO ATTRIBUTES: NONE 24 SEA FILE=REGISTRY SUB=L10 SSS FUL L15 L17 L20 8 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L17 => D L20 IBIB ABS HITSTR 1-8

# ACCESSION NUMBER: DOCUMENT NUMBER: 150:5994 TITLE: Studies on DNA dynamics using 2-N-tert-butylaminoxylpurines AUTHOR(S): Aso, Mariko; Mirc, John Walter; Kurita, Manami; Koga, Noboru; Suemune, Hiroshi CORPORATE SOURCE: Graduate School of Pharmaceutical Sciences, Kyushu

University, Maidashi, Higashi-ku, Fukuoka, 812-8582,

L20 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN

**Page 7 of 58** 

Japan

SOURCE: Nucleic Acids Symposium Series (2007), (51), 163-164

CODEN: NASSCJ; ISSN: 1746-8272

URL: http://nass.oxfordjournals.org/content/vol51/issu

e1/index.dtl

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal; (online computer file)

LANGUAGE: English

OTHER SOURCE(S): CASREACT 150:5994

GΙ

AB A symposium report. 2-N-tert-Butylaminoxylpurines I and II were synthesized from 2'-deoxy-6-chloropurine derivative III by lithiation strategy. Effects of motion of I and II on EPR spectra were studied by EPR measurement in sucrose solution at various temps. The single stranded and duplexed 15-mers containing I showed the clear difference in the EPR spectra to indicate I has the potential to accurately study the dynamics of purine residues.

IT 1083322-84-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tert-butylaminoxylpurines, EPR spectra, incorporation into DNA and subsequent duplex formation)

RN 1083322-84-2 HCAPLUS

Guanosine, N-(acetyloxy)-5'-0-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-N-(1,1-dimethylethyl)-, 3'-[2-cyanoethyl]

N, N-bis(1-methylethyl) phosphoramidite] 6-(N, N-diphenylcarbamate) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2005:1106792 HCAPLUS Full-text

DOCUMENT NUMBER: 143:379802

TITLE: Antisense oligonucleotides modulating transcription

factor  $AP-2\gamma$  (TFAP2C) expression for treatment

of proliferative diseases and cancer

INVENTOR(S): Bennett, C. Frank; Baker, Brenda F.; Dean, Nicholas

M.; Monia, Brett P.; Freier, Susan M.; Karras, James G.; Zhang, Hong; Murray, Susan F.; Butler, Madeline M.; Koller, Erich; Condon, Thomas P.; Gaarde, William

A.; Watt, Andrew T.; Graham, Mark J.; Wyatt,

Jacqueline R.; Cowsert, Lex M.; Dobie, Kenneth W.;

Roach, Mark P.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S.

Ser. No. 33,742. CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 326

PATENT INFORMATION:

PA:	TENT	NO.			KIN	D	DATE		APPLICATION NO.				DATE					
US	2005	0227:	938		A1	_	2005	1013		 US 2	004-	 1519.	3			20041217		
AU	9726	244			Α		1997	1106		AU 1	997-	2624	19970624					
AU	7137	40			В2		19991209											
US	6007	995			Α		1999	9991228 US 1998-106038					19980626					
US	6232	463			В1		2001	0515	US 1998-128508					19980804				
WO	2000	0005	04		A1		2000	0106	WO 1999-US13763				19990617					
	W:	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	BG,	BR,	BY,	CA,	CH,	CN,	CU,	CZ,	DE,	
		DK,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	
		ΚE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MD,	MG,	MK,	MN,	
		MW,	MX,	NO,	NΖ,	PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	
		TR,	TT,	UA,	UG,	US,	UΖ,	VN,	YU,	ZW								
	RW:	GH,	GM,	ΚE,	LS,	MW,	SD,	SL,	SZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,	DE,	DK,	
		ES,	FI,	FR,	GB,	GR,	ΙE,	ΙΤ,	LU,	MC,	NL,	PT,	SE,	BF,	ВJ,	CF,	CG,	
		CI,	CM,	GA,	GN,	GW,	ML,	MR,	ΝE,	SN,	TD,	TG						
US	2003	0044	979		A1		2003	0306		US 2	001-	8283	44		2	0010	405	
US	2003	0083	279		A1		2003	0501		US 2	001-	9101	85		2	0010	718	
US	2003	0109	466		A1		2003	0612		US 2	001-	9610	01		2	0010	920	
US	2003	0100	524		A1		2003	0529		US 2	001-	1614	9	20011101				

Serial#: 10/553,948						
US 20030125274	A1	20030703	US	2001-6911		20011108
US 20030105040	A1	20030605		2001-993731		20011113
US 20030125271	A1	20030703	US	2001-213		20011114
US 20030109467	A1	20030612	US	2001-2491		20011115
US 20030105041	A1	20030605	US	2001-1844		20011116
US 20030125272	A1	20030703	US	2001-1863		20011119
US 20030139359	A1	20030724	US	2001-6972		20011204
US 20030114400	A1	20030619	US	2001-3354		20011206
US 20030114401	A1	20030619	US	2001-3919		20011206
US 20030138952	A1	20030724	US	2001-17621		20011207
US 20030113914	A1	20030619	US	2001-6430		20011210
US 20030144224	A1	20030731	US	2001-20478		20011213
US 20030134809	A1	20030717	US	2001-24369		20011217
US 20030147863	A1	20030807	US	2001-23782		20011217
US 20030144225	A1	20030731	US	2001-33742		20011228
PRIORITY APPLN. INFO.:			US	1998-106038	A1	19980626
				1999-US13763		19990617
				2000-695451		20001024
				2001-828344		20010405
			US	2001-910185		20010718
				2001-961001		20010920
				2001-16149		20011101
				2001-6911		20011108
				2001-993731		20011113
				2001-213		20011114
				2001-2491		20011115
				2001-1844		20011116
				2001-1863		20011119
				2001-6972		20011204
				2001-3354		20011206
				2001-3919		20011206
				2001-17621		20011207
				2001-6430		20011210
				2001-20478		20011213
				2001-23782		20011217
				2001-24369		20011217
				2001-33742		20011228
			AU	1993-38025	A3	19930225

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Antisense compds., compns. and methods are provided for modulating the expression of transcription factor AP-2 $\gamma$  (TFAP2C) . The compns. comprise antisense compds., particularly antisense oligonucleotides, targeted to nucleic acids encoding TFAP2C. Antisense oligonucleotides were designed targeting different regions of the TFAP2C mRNA sequence and may be modified to contain phosphorothioate linkages, 2'-Omethoxyethyl sugar moiety, and 5-methylcytosine bases. The chimeric phosphorothioate antisense oligonucleotides have 2'-MOE wings and a deoxy gap. invention provides methods for synthesis of the antisense oligonucleotides. The antisense oligonucleotides demonstrated up to 91% inhibition of human TFAP2C expression. Methods of using these compds. for modulation of TFAP2C expression and for treatment of diseases associated with expression of TFAP2C are provided. TΤ

US 1997-948151

A1 19971009

1056984-88-3 1056984-89-4

RL: PRPH (Prophetic)

(Antisense oligonucleotides modulating transcription factor AP-2y (TFAP2C) expression for treatment of proliferative diseases and cancer)

1056984-88-3 HCAPLUS RN

INDEX NAME NOT YET ASSIGNED CN

Absolute stereochemistry.

RN 1056984-89-4 HCAPLUS CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L20 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2002:337381 HCAPLUS Full-text

DOCUMENT NUMBER: 137:105289

TITLE: Watson-Crick Base-Pairing Properties of Tricyclo-DNA

AUTHOR(S): Renneberg, Dorte; Leumann, Christian J.

CORPORATE SOURCE: Department of Chemistry and Biochemistry, University

of Bern, Bern, CH-3012, Switz.

SOURCE: Journal of the American Chemical Society (2002),

124(21), 5993-6002

CODEN: JACSAT; ISSN: 0002-7863

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 137:105289

AB Tricyclo-DNA belongs to the family of conformationally restricted oligodeoxynucleotide analogs. It differs structurally from DNA by an addnl. ethylene bridge between the centers C(3') and C(5') of the nucleosides, to which a cyclopropane unit is fused for further enhancement of structural rigidity. The synthesis of the hitherto unknown tricyclodeoxynucleosides containing the bases

cytosine and guanine and of the corresponding phosphoramidite building blocks is described, as well as a structural description of a representative of an  $\alpha$ - and a  $\beta$ tricyclodeoxynucleoside by x-ray anal. Tricyclodeoxynucleoside building blocks of all four bases were used for the synthesis of fully modified mixed-base oligonucleotides. Their Watson-Crick pairing properties with complementary DNA, RNA, and with itself were investigated by UV melting curves, CD spectroscopy, and mol. modeling. Tricyclo-DNA was found to be a very stable Watson-Crick base-pairing system. A UV melting curve anal. of the decamers tcd(pcgtgacagtt) and tcd(paactgtcacg) showed increased thermal stabilities of up to  $\Delta Tm/mod. = +1.2^{\circ}$  with complementary DNA and  $+2.4^{\circ}$  with complementary RNA. With itself, tricyclo-DNA showed an increase in stability of +3.1°/base pair relative to DNA. Investigations into the thermodn. properties of these decamers revealed an entropic stabilization and an enthalpic destabilization for the tricyclo-DNA/DNA duplexes. CD spectroscopic structural investigations indicated that tricyclo-DNA containing duplexes preferably exist in an A-conformation, a fact which is in agreement with results from mol. modeling.

IT 440115-29-7P 440115-33-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(tricyclo-DNA forms Watson-Crick base-pairs and shows enhanced thermal stability)

RN 440115-29-7 HCAPLUS

CN Carbamic acid, diphenyl-, 9-[(2S,3aS,4aS,5aR,5bS)-5a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-3a[(trimethylsilyl)oxy]cyclopropa[4,5]cyclopenta[1,2-b]furan-2-yl]-2-[(2-methylpropyl)amino]-9H-purin-6-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 440115-33-3 HCAPLUS
CN Carbamic acid, diphenyl-, 9-[(2R,3aS,4aS,5aR,5bS)-5a-[[(1,1-dimethylethyl)dimethylsilyl]oxy]octahydro-3a[(trimethylsilyl)oxy]cyclopropa[4,5]cyclopenta[1,2-b]furan-2-yl]-2-[(2-methylpropyl)amino]-9H-purin-6-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 48 THERE ARE 48 CAPLUS RECORDS THAT CITE THIS

RECORD (48 CITINGS)

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2001:614293 HCAPLUS  $\underline{\text{Full-text}}$ 

DOCUMENT NUMBER: 135:190437

TITLE: Antisense oligonucleotide modulation of Her-3 gene

expression

INVENTOR(S): Bennett, C. Frank; Cowsert, Lex M. PATENT ASSIGNEE(S): Isis Pharmaceuticals, Inc., USA

SOURCE: U.S., 49 pp. CODEN: USXXAM

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA	TENT	NO.			KIN	D	DATE			APPL	ICAT	ION 1	NO.		D	ATE	
US	6277	 640			B1	_	2001	0821		US 2	000-	 6307	 06		2	0000	 731
WO	2002	0104	09		A1		2002	0207		WO 2	001-	US22	751		2	0010	718
	W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	ΑZ,	BA,	BB,	ВG,	BR,	BY,	BZ,	CA,	CH,	CN,
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EE,	ES,	FI,	GB,	GD,	GE,	GH,	GM,
		HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	LS,
		LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NZ,	PL,	PT,	RO,
		RU,	SD,	SE,	SG,	SI,	SK,	SL,	ТJ,	TM,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,
		VN,	YU,	ZA,	ZW												
	RW:	GH,	GM,	ΚE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZW,	ΑT,	BE,	CH,	CY,
		DE,	DK,	ES,	FI,	FR,	GB,	GR,	ΙE,	IT,	LU,	MC,	NL,	PT,	SE,	TR,	BF,
		ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG	
AU	2001	0770	03		Α		2002	0213		AU 2	001-	7700.	3		2	0010	718
PRIORIT	Y APP	LN.	INFO	.:						US 2	000-	6307	06	Ž	A 2	0000	731
										WO 2	001-	US22	751	Ī	w 2	0010	718

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Antisense compds., compns. and methods are provided for inhibiting the expression of Her-3 protein of human. The compns. comprise antisense compds., particularly antisense oligonucleotides, targeted to nucleic acids encoding Her-3. Methods of using these compds. for inhibition of Her-3 expression and for treatment of diseases associated with expression of Her-3 are provided.

IT 1098518-67-2

RL: PRPH (Prophetic)

(Antisense oligonucleotide modulation of Her-3 gene expression)

RN 1098518-67-2 HCAPLUS

CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2000:252686 HCAPLUS Full-text

DOCUMENT NUMBER: 133:74242

TITLE: Chemical Synthesis of Cross-Link Lesions Found in

Nitrous Acid Treated DNA: A General Method for the Preparation of N2-Substituted 2'-Deoxyguanosines

AUTHOR(S): Harwood, Eric A.; Hopkins, Paul B.; Sigurdsson, Snorri

Th.

CORPORATE SOURCE: Department of Chemistry, University of Washington,

Seattle, WA, 98195, USA

SOURCE: Journal of Organic Chemistry (2000), 65(10), 2959-2964

CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 133:74242

GΙ

#### \* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Treatment of DNA with nitrous acid results in the formation of DNA-DNA cross-links. Two cross-link lesions have previously been isolated and their structures assigned based on spectroscopic data. The major lesion has been proposed to consist of two deoxyguanosine (dG) nucleosides sharing a common N2 atom I, while the structure of the minor lesion has been proposed to consist of a common nitrogen atom linking C2 of a dG nucleoside to C6 of deoxyadenosine II. The chemical synthesis of I and II, utilizing a palladium-catalyzed coupling, is described herein. It is demonstrated that the spectroscopic properties of synthetic I are identical to that of lesion I obtained from nitrous acid cross-linked DNA, thus providing a proof of its structure. Comparison of the limited spectroscopic data available for lesion II originating from nitrous acid cross-linked DNA to synthetic II supports its

structural assignment. The synthetic approach used for synthesis of I and II is shown to be a general method for the preparation of a variety of N2-substituted dG nucleosides in good yields.

ΙT 278803-37-5P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of N2-substituted 2'-deoxyguanosines cross-link lesions found in nitrous acid treated DNA)

278803-37-5 HCAPLUS RN

Guanosine, N-butyl-2'-deoxy-3',5'-bis-O-[(1,1-dimethylethyl)dimethylsilyl]-CN 6-O-(phenylmethyl) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



THERE ARE 42 CAPLUS RECORDS THAT CITE THIS OS.CITING REF COUNT: 42

RECORD (42 CITINGS)

THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 31

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN 1996:54407 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 124:139500

ORIGINAL REFERENCE NO.: 124:25787a,25790a

TITLE: Inhibition of HIV-1 RNase H activity by nucleotide

dimers and monomers

AUTHOR(S): Allen, S. J. W.; Krawczyk, S. H.; McGee, L. R.;

> Bischofberger, N.; Mulato, A. S.; Cherrington, J. M. Gilead Sciences, Inc., Foster City, CA, 94404, USA

CORPORATE SOURCE: Antiviral Chemistry & Chemotherapy (1996), 7(1), 37-45

SOURCE:

CODEN: ACCHEH; ISSN: 0956-3202

PUBLISHER: Blackwell Journal DOCUMENT TYPE: English LANGUAGE:

Nucleotide dimers and monomers were shown to inhibit human immunodeficiency virus AΒ type 1 (HIV) RNase H activity. Several effective inhibitors were identified and placed into three general groups based on biochem. characterization of their inhibition. The first group (group A) inhibited HIV RNase H and the closely related feline immunodeficiency virus (FIV) RNase H, but did not inhibit less related retroviral or cellular RNases H or HIV reverse transcriptase (RT). The second group (group B) inhibited the RNase H activity of several retroviruses as well as the reverse transcriptase function of HIV RT. The third group (group C) inhibited RNases H from retroviral and cellular sources but did not inhibit HIV RT. Kinetic analyses of HIV RNase H inhibition were conducted and all three types of inhibitors exhibited a competitive mode of inhibition with regard to substrate. The small nucleotides described here represent the most potent (Ki values from 0.57 to  $16~\mu M$ ) and selective inhibitors of HIV RNase H reported to date. Further structure -

function analyses of these mols. may lead to the discovery of unique, potent antiretroviral therapeutics.

IT 173291-39-9 173291-41-3 173291-44-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(inhibition of HIV-1 RNase H activity by nucleotide dimers and monomers)  $\$ 

RN 173291-39-9 HCAPLUS

CN Guanosine, 2'-deoxy-P-thioadenylyl-(3' $\rightarrow$ 5')-N-butyl-N-methyl-6-0-[2-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

RN 173291-41-3 HCAPLUS

CN Guanosine, 2'-deoxy-2'-fluoro-P-thioadenylyl-(3' $\rightarrow$ 5')-N,N-dibutyl-6-O-[2-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-B

RN 173291-44-6 HCAPLUS
CN Guanosine, N,N-dibutyl-6-O-[2-(4-nitrophenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS

RECORD (11 CITINGS)

L20 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1993:60029 HCAPLUS Full-text

DOCUMENT NUMBER: 118:60029

ORIGINAL REFERENCE NO.: 118:10787a,10790a

TITLE: Efficient regioselective synthesis of guanosine

analogs

AUTHOR(S): Jenny, Thomas F.; Benner, Steven A.

CORPORATE SOURCE: Lab. Org. Chem., ETH, Zurich, CH-8092, Switz. SOURCE: Tetrahedron Letters (1992), 33(44), 6619-20

CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 118:60029

GΙ

AB Reaction conditions are presented that allow regioselective introduction (N9 vs. N7) of guanine into sugar analogs under Vorbrueggen conditions. Using these conditions, a set of N2-protected guanosine analogs I (R = Bz, Ac; R1 = SBz, OBz, OAc) was prepared using isobutyryl[(nitrophenyl)ethyl]guanine II as the nucleophile. This approach helps solve an important synthetic problem in the preparation of guanosine analogs.

IT 145370-53-2P 145370-57-6P 145370-58-7P 145370-61-2P 145370-62-3P 145370-63-4P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and cleavage of nitrophenylethyl group of)

RN 145370-53-2 HCAPLUS

CN Benzenecarbothioic acid, S-[[2-[2-(benzoyloxy)ethyl]tetrahydro-5-[2-[(2-methylpropyl)amino]-6-[2-(4-nitrophenyl)ethoxy]-9H-purin-9-yl]-3-furanyl]methyl] ester,  $(2\alpha, 3\beta, 5\beta)$ - (9CI) (CA INDEX NAME)

Relative stereochemistry.

RN 145370-57-6 HCAPLUS

CN 2-Furanethanol, 3-[(benzoyloxy)methyl]tetrahydro-5-[2-[(2-methylpropyl)amino]-6-[2-(4-nitrophenyl)ethoxy]-9H-purin-9-yl]-, acetate (ester),  $(2\alpha, 3\beta, 5\beta)$ - (9CI) (CA INDEX NAME)

RN 145370-58-7 HCAPLUS

CN 2-Furanethanol, 3-[(acetyloxy)methyl]tetrahydro-5-[2-[(2-methylpropyl)amino]-6-[2-(4-nitrophenyl)ethoxy]-9H-purin-9-yl]-, benzoate (ester),  $(2\alpha, 3\beta, 5\beta)$ - (9CI) (CA INDEX NAME)

RN 145370-61-2 HCAPLUS

CN Benzenecarbothioic acid, S-[[2-[2-(benzoyloxy)ethyl]tetrahydro-5-[2-[(2-methylpropyl)amino]-6-[2-(4-nitrophenyl)ethoxy]-9H-purin-9-yl]-3-furanyl]methyl] ester,  $(2\alpha, 3\beta, 5\alpha)$ - (9CI) (CA INDEX NAME)


Relative stereochemistry.

RN 145370-62-3 HCAPLUS

CN 2-Furanethanol, 3-[(benzoyloxy)methyl]tetrahydro-5-[2-[(2-methylpropyl)amino]-6-[2-(4-nitrophenyl)ethoxy]-9H-purin-9-yl]-, acetate (ester),  $(2\alpha, 3\beta, 5\alpha)$ - (9CI) (CA INDEX NAME)

RN 145370-63-4 HCAPLUS

CN 2-Furanethanol, 3-[(acetyloxy)methyl]tetrahydro-5-[2-[(2-methylpropyl)amino]-6-[2-(4-nitrophenyl)ethoxy]-9H-purin-9-yl]-, benzoate (ester),  $(2\alpha, 3\beta, 5\alpha)$ - (9CI) (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L20 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1989:528695 HCAPLUS Full-text

DOCUMENT NUMBER: 111:128695

ORIGINAL REFERENCE NO.: 111:21427a,21430a

TITLE: 06-substituted-2'-deoxyguanosine-3'-phosphate adducts

detected by phosphorus-32 post-labeling of styrene

oxide treated DNA

AUTHOR(S): Pongracz, K.; Kaur, S.; Burlingame, A. L.; Bodell, W.

J.

CORPORATE SOURCE: Brain Tumor Res. Cent., Univ. California, San

Francisco, CA, 94143, USA

SOURCE: Carcinogenesis (1989), 10(6), 1009-13

CODEN: CRNGDP; ISSN: 0143-3334

DOCUMENT TYPE: Journal LANGUAGE: English

AB 32P post-labeling of DNA reacted with styrene oxide resulted in the detection of six adducts. To determine which of these corresponded to modification at the O6-position of guanine, O6-substituted styrene oxide-deoxyguanosine-3'-monophosphate derivs. were synthesized. The two synthetic isomers were purified by HPLC and the structures were confirmed by mass spectrometry and 1H NMR. 32P post-labeling and co-chromatog. with the DNA-styrene-7,8-oxide reaction products resulted in the assignment of 2 adducts as O6-(2-hydroxy-2-phenylethyl)-2'-deoxyguanosine-3',5'-bisphosphate and O6-(2-hydroxy-1-phenylethyl)-2'-deoxyguanosine-3',5'- bisphosphate.

II 122219-71-0P 122219-72-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 122219-71-0 HCAPLUS

CN 3'-Guanylic acid, 6-0-[2-(acetyloxy)-1-phenylethyl]-5'-0-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 122219-72-1 HCAPLUS

CN 3'-Guanylic acid, 6-0-[2-(acetyloxy)-2-phenylethyl]-5'-0-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)

# STRUCTURE SEARCH-PT.II

#### => => FILE REG

FILE 'REGISTRY' ENTERED AT 17:35:03 ON 19 APR 2010 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8 DICTIONARY FILE UPDATES: 18 APR 2010 HIGHEST RN 1219538-51-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 8, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> D STAT QUE L19

1 SEA FILE=REGISTRY SPE=ON ABB=ON PLU=ON "O6-METHYL-2'-DEOXYGU ANOSINE"/CN

=> D IDE CAN L19

# L19 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2010 ACS on STN

RN 964-21-6 REGISTRY

ED Entered STN: 16 Nov 1984

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 9H-Purine, 2-amino-9-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-6-methoxy-(8CI)

CN 9H-Purine, 2-amino-9-(2-deoxy- $\beta$ -D-ribofuranosyl)-6-methoxy- (7CI) OTHER NAMES:

CN 2'-Deoxy-6-methylguanosine

CN 2-Amino-6-methoxy-9-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)purine

CN 6-O-Methyl-2'-deoxyguanosine

CN 6-O-Methyldeoxyguanosine

CN 06-Methyl-2'-deoxyguanosine

CN O6-Methyldeoxyguanosine

FS STEREOSEARCH

MF C11 H15 N5 O4

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, CA, CAPLUS, CASREACT, CHEMCATS, CSCHEM, MEDLINE, RTECS\*, SPECINFO, TOXCENTER, USPAT2, USPATFULL

(\*File contains numerically searchable property data)

Absolute stereochemistry.

#### \*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

152 REFERENCES IN FILE CA (1907 TO DATE)

6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

152 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1: 152:254483

REFERENCE 2: 151:306603

REFERENCE 3: 148:71348

REFERENCE 4: 147:516635

REFERENCE 5: 146:310787

REFERENCE 6: 146:222036

REFERENCE 7: 146:206572

REFERENCE 8: 146:21366

REFERENCE 9: 144:462125

REFERENCE 10: 144:446191

#### => FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 17:44:35 ON 19 APR 2010 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

#### => D STAT QUE L38

L19	1	SEA FILE=REGIST	RY SPE=ON	I ABB=ON	PLU=ON	"O6-METHYL-2'-DEOXYGU
		ANOSINE"/CN				
L33	152	SEA FILE=HCAPLU	S SPE=ON	ABB=ON	PLU=ON	L19
L34	33522	SEA FILE=HCAPLU	S SPE=ON	ABB=ON	PLU=ON	IMMUNOSTIMULATION+PFT/
		CT OR IMMUNOSTI	M?/BI			
L35	53933	SEA FILE=HCAPLU	S SPE=ON	ABB=ON	PLU=ON	ANTISENS?/CT OR
		(ANTI(W)SENS? (	R ANTISEN	IS?)/BI		
L36	152611	SEA FILE=HCAPLU	S SPE=ON	ABB=ON	PLU=ON	OLIGONUCLEOTIDES+OLD, N
		T, PFT/CT OR OLI	GONUCLEO?	/BI		
L37	18678	SEA FILE=HCAPLU	S SPE=ON	ABB=ON	PLU=ON	(CPG? OR $C(W)P(W)G?)/B$
		Т				

L38 18 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L33 AND ((L34 OR L35 OR L36 OR L37))

=> D L38 IBIB ABS HITIND HITSTR 1-18

L38 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:996144 HCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 151:306603

TITLE: Cytosine Methylation Effects on the Repair of

O6-Methylguanines within CG Dinucleotides

AUTHOR(S): Guza, Rebecca; Ma, Linan; Fang, Qingming; Pegg,

Anthony E.; Tretyakova, Natalia

CORPORATE SOURCE: Department of Medicinal Chemistry, University of

Minnesota, Minneapolis, MN, 55455, USA

SOURCE: Journal of Biological Chemistry (2009), 284(34),

22601-22610

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

Biology

DOCUMENT TYPE: Journal LANGUAGE: English

AB O6-Alkyldeoxyguanine adducts induced by tobacco-specific nitrosamines are repaired by O6-alkylguanine DNA alkyltransferase (AGT), which transfers the O6-alkyl group from the damaged base to a cysteine residue within the protein. In the present study, a mass spectrometry-based approach was used to analyze the effects of cytosine methylation on the kinetics of AGT repair of O6-methyldeoxyguanosine (O6-Me-dG) adducts placed within frequently mutated 5'-CG-3' dinucleotides of the p53 tumor suppressor gene. O6-Me-dG-containing DNA duplexes were incubated with human recombinant AGT protein, followed by rapid quenching, acid hydrolysis, and isotope dilution high-pressure liquid chromatog.-electrospray ionization tandem mass spectrometry anal. of unrepaired O6-methylguanine. Second-order rate consts. were calculated in the absence or presence of the C-5 Me group at neighboring cytosine residues. The kinetics of AGT-mediated repair of O6-Me-dG were affected by neighboring 5-methylcytosine (MeC) in a sequence-dependent manner. AGT repair of O6-Me-dG adducts placed within 5'-CG-3' dinucleotides of p53 codons 245 and 248 was hindered when MeC was present in both DNA strands. In contrast, cytosine methylation within p53 codon 158 slightly increased the rate of O6-Me-dG repair by AGT. The effects of MeC located immediately 5' and in the base paired position to O6-Me-dG were not additive as revealed by expts. with hypomethylated sequences. Furthermore, differences in dealkylation rates did not correlate with AGT protein affinity for cytosine-methylated and unmethylated DNA duplexes or with the rates of AGT-mediated nucleotide flipping, suggesting that MeC influences other kinetic steps involved in repair, e.g., the rate of alkyl transfer from DNA to AGT.

CC 4-6 (Toxicology)

IT Oligonucleotides

RL: BSU (Biological study, unclassified); BIOL (Biological study) (dinucleotides; cytosine methylation effects on repair of methylguanines within CG dinucleotides)

IT 964-21-6, O6-Methyldeoxyguanosine 77271-19-3, O6-Alkylguanine DNA alkyltransferase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cytosine methylation effects on repair of methylguanines within CG dinucleotides)

IT 964-21-6, O6-Methyldeoxyguanosine

RL: BSU (Biological study, unclassified); BIOL (Biological study) (cytosine methylation effects on repair of methylguanines within CG dinucleotides)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2007:1087274 HCAPLUS Full-text

DOCUMENT NUMBER: 147:516635

TITLE: Model transition states for methane diazonium ion

 $\hbox{methylation of guanine runs in oligomeric DNA}\\$ 

AUTHOR(S): Ekanayake, Kaushalya S.; Lebreton, Pierre R. CORPORATE SOURCE: Department of Chemistry, University of Illinois,

Chicago, IL, 60607-7061, USA

SOURCE: Journal of Computational Chemistry (2007), 28(14),

2352-2365

CODEN: JCCHDD; ISSN: 0192-8651

PUBLISHER: John Wiley & Sons, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

AB The DNA reaction pattern of the methane diazonium ion, which is the reactive intermediate formed from several carcinogenic methylating agents, was examined at N7 and O6 sites in guanine runs occurring in oligonucleotides and model oligonucleotides. D. functional B3LYP/6-31G\*, and SCF 3-21G and STO-3G energies of model transition states were calculated in the gas phase and in the CPCM reaction field. For nucleotides containing two, three, and four stacked quanines with counterions in the gas phase, O6 reactivity is greater than N7 reactivity. In the reaction field, N7 reactivity is 9.0 to 9.8 times greater than 06 reactivity. For a double-stranded oligonuclectide containing two stacked quanines with counterions in the reaction field, the N7 and O6 reactivities of the 3'-guanine are 3.9 times greater than the corresponding sites in the 5'-guanine. For double-stranded oligonucleotides with three or four stacked quanines and counterions, the reactivities of the interior quanines are higher than corresponding reactivities of quanines at the ends. These reaction patterns agree with most of the available exptl. data. Activation energy decomposition anal. for gas-phase reactions in a double-stranded dinucleotide containing two stacked guanines with counterions indicates that selectivity at 06 is almost entirely due to electrostatic forces. Selectivity at N7 also has a large electrostatic interaction. However, the orbital interaction also contributes significantly to the gas-phase selectivity, accounting for 32% of the total interaction energy difference between the 3'- and 5'-guanine reactions. In aqueous solution, the relative orbital contribution to N7 selectivity is likely to be larger.

CC 6-2 (General Biochemistry)

IT DNA

Oligodeoxyribonucleotides

RL: BSU (Biological study, unclassified); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)

(model transition states for methane diazonium ion methylation of quanine runs in oligomeric DNA)

IT 964-21-6, 06-Methyl 2'-deoxyguanosine 26718-69-4, N7-Methyl

TТ

2'-deoxyquanosine

RL: BSU (Biological study, unclassified); FMU (Formation, unclassified);

BIOL (Biological study); FORM (Formation, nonpreparative)

(model transition states for methane diazonium ion methylation of

quanine runs in oligomeric DNA) 964-21-6, 06-Methyl 2'-deoxyguanosine

RL: BSU (Biological study, unclassified); FMU (Formation, unclassified);

BIOL (Biological study); FORM (Formation, nonpreparative)


(model transition states for methane diazonium ion methylation of

quanine runs in oligomeric DNA)

964-21-6 HCAPLUS RN

CN Guanosine, 2'-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 63 THERE ARE 63 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN 2006:1349025 HCAPLUS Full-text

ACCESSION NUMBER:

DOCUMENT NUMBER: 146:222036

TITLE: Development of a novel site-specific mutagenesis assay

using MALDI-ToF MS (SSMA-MS)

AUTHOR(S): McLuckie, Keith I. E.; Lamb, John H.; Sandhu,

Jatinderpal K.; Pearson, Helen L.; Brown, Karen;

Farmer, Peter B.; Jones, Donald J. L.

CORPORATE SOURCE: The Biocentre, Cancer Biomarkers and Prevention Group,

University of Leicester, Leicester, LE1 7RH, UK

SOURCE: Nucleic Acids Research (2006), 34(22), e150/1-e150/12

CODEN: NARHAD; ISSN: 0305-1048

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal LANGUAGE: English

AΒ We have developed and validated a novel site-specific mutagenesis assay, termed SSMA-MS, which incorporates MALDI-ToF mass spectrometry (MALDI-MS) anal. as a means of determining the mutations induced by a single DNA adduct. The assay involves ligating an adducted deoxyoligonucleotide into supF containing pSP189 plasmid. The plasmid is transfected into human Ad293 kidney cells allowing replication and therefore repair or a mutagenic event to occur. Escherichia coli indicator bacteria are transformed with recovered plasmid and plasmids containing the insert are identified colorimetrically, as they behave as frameshift mutations. The plasmid is then amplified and digested using a restriction cocktail of Mboll and Mnll to yield 12 bp deoxyoligonucleotides, which are characterized by MALDI-MS. MALDI-MS takes advantage of the difference in mol. weight between bases to identify any induced mutations. This anal. method therefore provides qual. and quant. information regarding the type and frequency of mutations induced. This assay was developed and validated using an O6-methyl-2'-deoxyguanosine adduct, which induced the expected GC AT substitutions, when replicated in human or bacterial cells. This approach can be

applied to the study of any DNA adduct in any biol. relevant gene sequence (e.g. p53) in human cells and would be particularly amenable to high-throughput anal.

CC 3-1 (Biochemical Genetics)

IT Oligonucleotides

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (adduct-containing; development of novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS))

IT 964-21-6, 06-Methyl-2'-deoxyguanosine

RL: BSU (Biological study, unclassified); BIOL (Biological study) (mutagenesis induced by; development of novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS))

IT 964-21-6, O6-Methyl-2'-deoxyguanosine

RL: BSU (Biological study, unclassified); BIOL (Biological study) (mutagenesis induced by; development of novel site-specific mutagenesis assay using MALDI-ToF MS (SSMA-MS))

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2006:412032 HCAPLUS  $\underline{\text{Full-text}}$ 

DOCUMENT NUMBER: 144:446191

TITLE: Nucleic acid analysis by uses of mass labeled identification oligonucleotides and their

capture for subsequent identification by mass

spectrometry

INVENTOR(S): Grosveld, Franklin; Philipsen, Jacobus PATENT ASSIGNEE(S): Erasmus University Medical Center, Neth.

SOURCE: PCT Int. Appl., 53 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	E APPLICATI	ION NO.	DATE			
WO 2006046144	A2 2006	60504 WO 2005-	IB3513	20051026			
WO 2006046144	A3 2006	61123					
W: AE, AG, AL,	AM, AT, AU,	, AZ, BA, BB, BG,	BR, BW, BY, B	Z, CA, CH,			
CN, CO, CR,	CU, CZ, DE,	, DK, DM, DZ, EC,	EE, EG, ES, F	I, GB, GD,			
GE, GH, GM,	HR, HU, ID,	, IL, IN, IS, JP,	KE, KG, KM, K	P, KR, KZ,			
LC, LK, LR,	LS, LT, LU,	, LV, LY, MA, MD,	MG, MK, MN, M	.W, MX, MZ,			
NA, NG, NI,	NO, NZ, OM,	, PG, PH, PL, PT,	RO, RU, SC, S	D, SE, SG,			
SK, SL, SM,	SY, TJ, TM,	, TN, TR, TT, TZ,	UA, UG, US, U	Z, VC, VN,			

```
Serial#: 10/553,948
             YU, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
             CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
             GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:
                                            GB 2004-23873
                                                                A 20041027
     Described is a method for analyzing nucleic acid isolated from or in a biol. sample
     through the use of mass labeled identification oligonucleotides and their capture
     for subsequent identification by mass spectrometry. The method comprises the steps
     of hybridizing to the nucleic acid(s) under desired conditions in solution
     containing a repertoire of identification oligonucleotides, each of defined and
     different mass; capturing the nucleic acid onto a solid phase and washing off those
     members of the repertoire which are not hybridized to the nucleic acid with a
     desired affinity; and eluting the repertoire members which remain hybridized to
     nucleic acid after the washing step and analyzing said members to resolve their mass
     and/or quantity. The invention is of particular value for the simultaneous
     resolution of complex mixts. of oligonucleotides of similar or identical mass but
     different nucleotide sequence.
     ICM C12N
IC
    3-1 (Biochemical Genetics)
CC
     Section cross-reference(s): 9
     target nucleic acid hybridization mass labeled identification
ST
     oligonucleotide; mass spectrometry identification
     oligonucleotide nucleic acid hybridization
    Mass spectrometry
ΤТ
        (Fourier-transform; nucleic acid anal. by uses of mass labeled
        identification oligonucleotides and their capture for
        subsequent identification by mass spectrometry)
ΙT
     Time-of-flight mass spectrometry
        (matrix-assisted photodesorption-photoionization; nucleic acid anal. by
        uses of mass labeled identification oligonucleotides and
        their capture for subsequent identification by mass spectrometry)
     Oligonucleotides
ΙT
     RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (methylphosphonate-linked; nucleic acid anal. by uses of mass labeled
        identification oligonucleotides and their capture for
        subsequent identification by mass spectrometry)
    Mass spectrometry
ΤT
     Nucleic acid hybridization
        (nucleic acid anal. by uses of mass labeled identification
        oligonucleotides and their capture for subsequent
        identification by mass spectrometry)
ΙT
    Nucleoside analogs
       Oligonucleotides
       Peptide nucleic acids
       Phosphorothicate oligodeoxyribonucleotides
     RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (nucleic acid anal. by uses of mass labeled identification
        oligonucleotides and their capture for subsequent
        identification by mass spectrometry)
ΤТ
    Amines, biological studies
     RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (oligonucleotide terminus modified with; nucleic acid anal.
        by uses of mass labeled identification oligonucleotides and
```

their capture for subsequent identification by mass spectrometry)

(photodesorption, matrix-assisted, time-of-flight; nucleic acid anal.

Laser ionization mass spectrometry

ΙT

```
by uses of mass labeled identification oligonucleotides and
        their capture for subsequent identification by mass spectrometry)
     Laser desorption mass spectrometry
ΙT
        (photoionization, matrix-assisted, time-of-flight; nucleic acid anal.
        by uses of mass labeled identification oligonucleotides and
        their capture for subsequent identification by mass spectrometry)
     Nucleic acids
ΙT
     RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical
     study); BIOL (Biological study)
        (target; nucleic acid anal. by uses of mass labeled identification
        oligonucleotides and their capture for subsequent
        identification by mass spectrometry)
ΙT
     57-88-5D, Cholesterol, oligonucleotide terminus modified with
     66-97-7D, Psoralen, oligonucleotide terminus modified with
     260-94-6D, Acridine, oligonucleotide terminus modified with
     1672-46-4D, Digoxigenin, oligonucleotide terminus modified with
     2321-07-5D, Fluorescein, oligonucleotide terminus modified with
     3301-79-9D, 6-Fam, oligonucleotide terminus modified with
     6268-49-1D, Dabcyl, oligonucleotide terminus modified with
     13558-31-1D, oligonucleotide terminus modified with
     50402-56-7D, Edans, oligonucleotide terminus modified with
     82354-19-6D, Texas red, oligonucleotide terminus modified with
     82855-40-1D, Joe, eligonucleotide terminus modified with
     120718-39-0D, ROX, oligonucleotide terminus modified with
     120718-52-7D, Tamra, oligonucleotide terminus modified with
     138039-55-1, Cascade blue 146368-14-1D, Cy5, oligonucleotide
     terminus modified with 146368-16-3D, Cy3, oligonucleotide
     terminus modified with 155911-16-3D, Hex, oligonucleotide
     terminus modified with 192230-82-3D, Tet, oligonucleotide
     terminus modified with 885323-53-5D, oligonucleotide terminus
     modified with
     RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (nucleic acid anal. by uses of mass labeled identification
        oligonucleotides and their capture for subsequent
        identification by mass spectrometry)
     139868-33-0, GenBank X62302 140041-65-2, GenBank X03917 140337-44-6,
ΙT
     GenBank M60456 140530-23-0, GenBank X13752 140758-67-4, GenBank J00413
     194380-70-6, GenBank AF006492 204884-28-6, GenBank AF047339
     224358-99-0, GenBank AF028722 225636-20-4, GenBank AB020013
     225673-93-8, GenBank AF134811 322038-96-0, GenBank AK002286
     322290-53-9, GenBank AK012501 336087-75-3, GenBank AF364516
     382737-36-2, GenBank X01997 384408-50-8, GenBank V00714
     RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
     (Biological study)
        (nucleic acid anal. by uses of mass labeled identification
        oligonucleotides and their capture for subsequent
        identification by mass spectrometry)
     50-89-5D, Thymidine, biotin conjugates, biological studies 50-91-9
     54-42-2, 5-Iodo-2'-deoxyuridine 59-14-3, 5-Bromo-2'-deoxyuridine
     73-03-0, Cordycepin 452-06-2, 2-Aminopurine 611-53-0,
     5-Iodo-2'-deoxycytidine 838-07-3, 5-Methyl-2'-deoxycytidine 890-38-0,
     2'-Deoxyinosine 951-78-0, 2'-Deoxyuridine 964-21-6
     1022-79-3, 5-Bromo-2'-deoxycytidine 2002-35-9,
     N6-Methyl-2'-deoxyadenosine 3881-21-8, 2'-O-Methylinosine 4097-22-7,
     2',3'-Dideoxyadenosine 4546-68-3, 2'-Deoxynebularine 4546-70-7
     5930-94-9, 3-Nitropyrrole 6146-52-7, 5-Nitroindole 7236-57-9,
     4-Thiothymidine 7481-89-2, 2',3'-Dideoxycytidine 10356-76-0,
     5-Fluoro-2'-deoxycytidine 13389-03-2 14985-44-5,
8-Bromo-2'-deoxyadenosine 16096-32-5, 4-Methyl-indole
                                                               28585-51-5
     50591-13-4 60129-59-1, 7-Deaza-2'-deoxyadenosine 62471-63-0,
```


8-0xo-2'-deoxyadenosine 68045-42-1 86392-75-8, 95119-96-3 7-Deaza-2'-deoxyguanosine 88847-89-6, 8-Oxo-dG 109389-24-4 109389-25-5 113886-70-7 114485-36-8 126128-42-5, DP 179817-95-9 179817-96-0 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses) (oligonucleotides containing; nucleic acid anal. by uses of mass labeled identification oligonucleotides and their capture for subsequent identification by mass spectrometry) 885709-51-3 885709-52-4 885709-53-5 885709-54-6 TT 885709-55-7 885709-57-9 885709-58-0 885709-59-1 885709-56-8 885709-60-4 885709-61-5 885709-62-6 885709-63-7 885709-64-8 885709-65-9 885709-66-0 885709-67-1 885709-68-2 885709-69-3 885709-70-6 885709-71-7 885709-72-8 885709-73-9 885709-74-0 885709-75-1 885709-76-2 885709-77-3 885709-78-4 885709-79-5 885709-80-8 885709-81-9 885709-82-0 885709-83-1 885709-84-2 885709-85-3 885709-86-4 885709-87-5 885709-88-6 885709-89-7 885709-90-0 

 885709-91-1
 885709-92-2
 885709-93-3
 885709-94-4
 885709-95-5

 885709-96-6
 885709-97-7
 885709-98-8
 885709-99-9
 885710-00-9

  $885710 - 01 - 0 \qquad 885710 - 02 - 1 \qquad 885710 - 03 - 2 \qquad 885710 - 04 - 3 \qquad 885710 - 05 - 4$ 885710-06-5 885710-07-6 885710-08-7 885710-09-8 885710-10-1 885710-11-2 885710-12-3 885710-13-4 885710-14-5 885710-15-6 885710-16-7 885710-17-8 885710-18-9 RL: PRP (Properties) (unclaimed sequence; nucleic acid anal. by uses of mass labeled identification oligonucleotides and their capture for subsequent identification by mass spectrometry) ΙT 964-21-6 RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses) (oligonucleotides containing; nucleic acid anal. by uses of mass labeled identification eligonucleotides and their capture for subsequent identification by mass spectrometry) RN 964-21-6 HCAPLUS Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME) CN

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2005:427312 HCAPLUS Full-text

DOCUMENT NUMBER: 143:149197

TITLE: Separation of modified 2'-deoxyoligonucleotides using

ion-pairing reversed-phase HPLC

AUTHOR(S): Gelhaus, Stacy L.; LaCourse, William R.

CORPORATE SOURCE: Department of Chemistry and Biochemistry, University

of Maryland, Baltimore, MD, 21250, USA

SOURCE: Journal of Chromatography, B: Analytical Technologies

in the Biomedical and Life Sciences (2005), 820(2),

157-163

CODEN: JCBAAI; ISSN: 1570-0232

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

AB A group of 18-mers of the same base sequence, but with differing alkyl modifications is used to investigate effects of these modifications on retention of

oligonucleotides using ion-pairing reversed-phase liquid chromatog. (IP-RPLC). It is shown that IP-RPLC is able to distinguish between oligonucleotides differing only by a single alkyl group. The identity of the nucleobase and position and length of the alkyl adduct affect retention of the oligonucleotide. These separation phenomena result from changes in charge and hydrophobicity upon alkylation. As demonstrated in this paper; chromatog. selectivity, unique to IP-RPLC, greatly facilitates the purification process of modified oligonucleotides.

CC 9-3 (Biochemical Methods)

Section cross-reference(s): 3, 33

IT Oligodeoxyribonucleotides

RL: ANT (Analyte); BSU (Biological study, unclassified); PRP (Properties); PUR (Purification or recovery); ANST (Analytical study); BIOL (Biological study); PREP (Preparation)

(separation of modified 2'-deoxyoligonucleotides using ion-pairing reversed-phase HPLC)

IT 838-07-3D, oligonucleotide derivative 964-21-6D,

oligonucleotide derivative 2002-35-9D, oligonucleotide

derivative 50591-13-4D, oligonucleotide derivative 50704-46-6D,

oligonucleotide derivative 101803-03-6D, oligonucleotide

derivative 283600-46-4D, oligonucleotide derivative

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL

(Biological study)

(separation of modified 2'-deoxyoligonucleotides using ion-pairing reversed-phase HPLC)

IT 964-21-6D, oligonucleotide derivative

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)

(separation of modified 2'-deoxyoligonucleotides using ion-pairing reversed-phase HPLC)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2002:832909 HCAPLUS Full-text DOCUMENT NUMBER: 137:348832

TITLE: Mass spectrometric analysis of nucleic acids using

oligonucleotides modified with mass labels

INVENTOR(S):
Grosveld, Frank

PATENT ASSIGNEE(S): Erasmus Universiteit Rotterdam, Neth.

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

	PAT	CENT 1	NO.			KIN	D	DATE			APPI	ICAT	ION :	NO.		D.	ATE	
	WO	2002	0860	51		A2	_	2002	1031		WO 2	2002-	 IB22	98		2	0020	424
	WO	2002	0860	51		A3		2003	1120									
		W:	ΑE,	AG,	AL,	AM,	ΑT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BY,	BZ,	CA,	CH,	CN,
			CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	ES,	FΙ,	GB,	GD,	GE,	GH,
			GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	ΚE,	KG,	KP,	KR,	KΖ,	LC,	LK,	LR,
			LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NO,	NΖ,	OM,	PH,
												SL,						
			UA,	UG,	US,	UZ,	VN,	YU,	ZA,	ZM,	ZW	·	,	·	·		•	·
		RW:	GH,	GM,	KE,	LS,	MW,	MZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,
												CY,						
			•	•	•	•			•			BF,		•	•		•	
									SN,			,	- ,	- ,	,	- ,	- ,	- ,
	СА	2445	,	~ ,	,	,	,		,	,		2002-	2445	2.48		2	0020	424
	_	2002									-		_				0020	
		1385										2002-					0020	
												IT,						
		•	•	•	•	•	•	•	MK,	•	•	•	,	,		~_,	,	,
	.TP	2005										2002-	5835	67		2	0020	424
		2002															0020	
		2004															0020	
DD T ()		ZOO4				711		2001	0 / 1 3			001-					0010	-
11(10)	.\	L ALL.	T11/ •	TIME	• •						_	2001-		-			0010	
												2002-		-	_	_	0010	
												.002-				-	0020	

The present invention relates to nucleic acid anal. and in particular, but not AB exclusively, computational aspects of nucleic acid anal. The present invention provides a method for constructing a set, or repertoire, of sequence-specific binding mols. which are differentiable by mass. According to an aspect of the present invention, there is provided a method for constructing a repertoire of oligomers differentiable by mass, comprising: (a) providing a heterogeneous pool of monomers, wherein said monomers are modified by addition of one or more of a selection of mass labels; (b) optionally, providing a heterogeneous pool of unlabeled monomers; (c) determining the monomer sequences of the oligomers to be represented in the repertoire and calculating the number and nature of the mass labels to be incorporated into each monomer such that each oligomer differs in mass; and (d) assembling a plurality of labeled monomers and, optionally, one or more unlabeled monomers, to form the oligomers. The repertoire is constructed so that each oligomer with a different sequence has a different mass characteristic. members of the repertoire which hybridized to the nucleic acid can then be identified by a mass anal. In another aspect, the invention provides a method for analyzing nucleic acid in a biol. sample, comprising the steps of: (a) immobilizing the nucleic acid (s) in the sample onto a solid support; (b) hybridizing to the nucleic acid (s) at a desired stringency a repertoire of oligonucleotides, and eluting those members of the repertoire which do not hybridize at the desired stringency; (c) eluting the repertoire members hybridized in step (b) and analyzing said members to resolve their mass. A powerful technique to detect and quantify nucleic acid sequences based on the identification of oligomers according to their mass is provided. The technique does not suffer from the disadvantages associated with 32P-labeling or forming biotinylated or fluorescein-conjugated probes and when

```
Serial#: 10/553,948
     coupled with a mass spectrometric anal. gives rapid, precise and unambiguous
     results.
     ICM C12G
IC
CC
    9-16 (Biochemical Methods)
     Section cross-reference(s): 3
ST
     nucleic acid analysis oligonucleotide mass spectrometry label
ΙT
    Oligonucleotides
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (2'-O-Me, methylphosphonate-linked; mass spectrometric anal. of nucleic
        acids using oligonucleotides modified with mass labels)
ΙT
     RNA
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (2'-OMe; mass spectrometric anal. of nucleic acids using
        oligonucleotides modified with mass labels)
ΙT
     DNA
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (abasic site-containing, oligonucleotide base modification with;
        mass spectrometric anal. of nucleic acids using
        oligonucleotides modified with mass labels)
    Computer program
ΙT
     Computers
     Immobilization, molecular or cellular
     Mass spectrometry
     Nucleic acid hybridization
     Sequence homology analysis
     Time-of-flight mass spectrometry
        (mass spectrometric anal. of nucleic acids using
        oligonucleotides modified with mass labels)
ΙT
     DNA
     Nucleic acids
     RNA
     mRNA
     RL: ANT (Analyte); BSU (Biological study, unclassified); ANST (Analytical
     study); BIOL (Biological study)
        (mass spectrometric anal. of nucleic acids using
        oligonucleotides modified with mass labels)
ΙT
     Phosphorothicate oligonucleotides
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (mass spectrometric anal. of nucleic acids using
        oligonucleotides modified with mass labels)
    Oligonucleotides
ΤТ
     Oligopeptides
       Peptide nucleic acids
     Probes (nucleic acid)
     RL: ARG (Analytical reagent use); BUU (Biological use, unclassified); ANST
     (Analytical study); BIOL (Biological study); USES (Uses)
        (mass spectrometric anal. of nucleic acids using
        oligonucleotides modified with mass labels)
ΙT
    Amines, uses
     Thiols, uses
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (oligonucleotide modification with; mass spectrometric anal.
        of nucleic acids using oligonucleotides modified with mass
        labels)
ΙT
     Phosphates, uses
     RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (phosphorothioates, oligonucleotide backbone modification
        with; mass spectrometric anal. of nucleic acids using
        oligonucleotides modified with mass labels)
     Laser ionization mass spectrometry
ΙT
        (photodesorption, matrix-assisted; mass spectrometric anal. of nucleic
```

```
Serial#: 10/553,948
       acids using oligonucleotides modified with mass labels)
ΙT
    Laser desorption mass spectrometry
        (photoionization, matrix-assisted; mass spectrometric anal. of nucleic
       acids using oligonucleotides modified with mass labels)
ΙT
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (rDNA, oligonucleotide modification with; mass spectrometric
       anal. of nucleic acids using oligonucleotides modified with
       mass labels)
    138039-55-1
ΙT
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (Cascade Blue, oligonucleotide modification with; mass
       spectrometric anal. of nucleic acids using oligonucleotides
       modified with mass labels)
    146368-16-3, Cy3
ΙT
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (Cy3, oligonucleotide modification with; mass spectrometric
       anal. of nucleic acids using oligonucleotides modified with
       mass labels)
    146368-14-1, Cy5
TΤ
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (Cy5, oligonucleotide modification with; mass spectrometric
       anal. of nucleic acids using oligonucleotides modified with
       mass labels)
ΙT
    155911-16-3, HEX
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
       (HEX, oligonucleotide modification with; mass spectrometric
       anal. of nucleic acids using oligonucleotides modified with
       mass labels)
    120718-52-7, TAMRA
TΤ
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (mass spectrometric anal. of nucleic acids using
       oligonucleotides modified with mass labels)
    993-13-5
ΙT
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (oligonucleotide backbone modification with; mass
       spectrometric anal. of nucleic acids using eligonucleotides
       modified with mass labels)
     50-89-5D, DT, conjugates with biotin 50-91-9 54-42-2
ΙT
    73-03-0, Cordycepin 452-06-2, 2-Aminopurine 611-53-0 838-07-3
    890-38-0 951-78-0 964-21-6 1022-79-3 2002-35-9
    3881-21-8 4097-22-7 4546-68-3, 2'-Deoxynebularine 5930-94-9,
    3-Nitropyrrole 6146-52-7, 5-Nitroindole 7236-57-9 7481-89-2
    10356-76-0 13389-03-2 14985-44-5
                                         16096-32-5, 4-Methylindole
     28585-51-5 50591-13-4 60129-59-1
                                          62471-63-0
                                                      86392-75-8
    88847-89-6, 8-Oxo dG 109389-24-4 109389-25-5 113886-70-7
    114485-36-8 126128-42-5 179817-95-9 179817-96-0
    RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
        (oligonucleotide base modification with; mass spectrometric
       anal. of nucleic acids using oligonucleotides modified with
       mass labels)
ΙT
    51-28-5, Dinitrophenol, uses
                                 56-81-5, Glycerol, uses
    Cholesterol, uses 58-85-5D, Biotin, derivs. 66-97-7, Psoralen
     81-88-9 260-94-6, Acridine 1672-46-4, Digoxigenin 2321-07-5,
    Fluorescein 3301-79-9, 6-FAM 6268-49-1, Dabcyl 50402-56-7, Edans
```

82354-19-6, Texas Red 82855-40-1, JOE 120718-39-0, ROX 192230-82-3,

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (oligonucleotide modification with; mass spectrometric anal.

of nucleic acids using oligonucleotides modified with mass labels) Page 35 of 58

IT 4546-70-7

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (oligonucleotides containing; mass spectrometric anal. of nucleic acids using oligonucleotides modified with mass labels)

IT 123039-46-3 474235-91-1 474235-92-2 474235-93-3 474349-62-7

474349-63-8

RL: PRP (Properties)

(unclaimed sequence; mass spectrometric anal. of nucleic acids using oligonucleotides modified with mass labels)


IT 964-21-6

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) (oligonucleotide base modification with; mass spectrometric anal. of nucleic acids using oligonucleotides modified with mass labels)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD

(2 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2000:559575 HCAPLUS Full-text

DOCUMENT NUMBER: 133:335422

TITLE: Synthesis and Characterization of DNA Containing

06-Carboxymethylguanine

AUTHOR(S): Xu, Y.-Z.

CORPORATE SOURCE: Department of Biochemistry and Molecular Biology,

University College London, London, WC1E 6BT, UK

SOURCE: Tetrahedron (2000), 56(33), 6075-6081

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB O6-Carboxymethylguanine was formed in DNA treated with N-nitrosoglycocholic acid and believed to be implicated in human gastrointestinal and colorectal tumor. An efficient method is presented here for synthesis of oligodeoxynucleotides containing O6-carboxymethylguanine at pre-determined positions. The synthetic protocol also allows for production of oligomers containing O6-aminocarbonylmethylguanine. These guanine-modified oligomers have been fully characterized and could provide a useful tool for biol. studies of these modified bases.

CC 33-10 (Carbohydrates)

IT Oligodeoxyribonucleotides

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(guanine-modified; synthesis and characterization of DNA containing

06-carboxymethylquanine)

IT 964-21-6P 120022-79-9P 189457-82-7P 189457-83-8P

302584-91-4P 302584-93-6P 302584-95-8P 302584-97-0P 302585-01-9P

302585-05-3P 302585-07-5P 302585-13-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(synthesis and characterization of DNA containing O6-carboxymethylguanine) IT 964-21-6P

IT 964-21-6F

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis and characterization of DNA containing O6-carboxymethylguanine) RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1998:479638 HCAPLUS Full-text

DOCUMENT NUMBER: 129:91400

ORIGINAL REFERENCE NO.: 129:18739a,18742a

TITLE: Method for polynucleotide amplification using modified

oligonucleotide primers having a

non-extendable 3'-end

INVENTOR(S): Ullman, Edwin F.; Lishanski, Alla; Kurn, Nurith

PATENT ASSIGNEE(S): Dade Behring Marburg G.m.b.H., Germany

SOURCE: PCT Int. Appl., 85 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND DATE	APPLICATION NO.	DATE
WO 9828443 W: CA, JP	A1 19980702	WO 1997-US23706	19971217
	DE, DK, ES, FI, E	FR, GB, GR, IE, IT, LU,	MC, NL, PT, SE
US 6482590	B1 20021119	US 1997-965492	19971106
CA 2246225	A1 19980702	CA 1997-2246225	19971217
EP 904412	A1 19990331	EP 1997-952592	19971217
EP 904412	B1 20011010		
R: AT, BE, CH,	DE, DK, ES, FR, C	GB, GR, IT, LI, LU, NL,	SE, MC, PT,
IE, FI			
AT 206766	T 20011015	AT 1997-952592	19971217

```
Serial#: 10/553,948
                         T 20020129 JP 1998-529035
T3 20020316 ES 1997-952592
     JP 2002503089
                                                                   19971217
     ES 2165634
                                                                   19971217
                                20020429 PT 1997-952592
     PT 904412
                         E
                                                                   19971217
                                            US 1996-33137P
                                                               P 19961220
PRIORITY APPLN. INFO.:
                                                               A 19971106
                                            US 1997-965492
                                            US 1996-33137
                                                               P 19961220
                                                               W 19971217
                                            WO 1997-US23706
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
     The present invention relates to a method for selectively extending an
     oligonucleotide primer along a specific target polynucleotide sequence in a mixture
     of polynucleotides. The method comprises providing the modified oligonucleotide
     having a 3'-end that is not extendable along any polynucleotide and extending the
     oligonucleotide primer selectively along the specific target polynucleotide sequence
     by controlling the degradation of the 3'-end of the modified oligonucleotide.
     this way extension along polynucleotides other than the specific target
     polynucleotide sequence is substantially reduced or avoided. In another aspect the
     invention is an improvement in a method for amplifying a target polynucleotide
     sequence. The improvement comprises deriving the oligonucleotide primer from a
     modified oligonacleotide having a portion that hybridizes to the target
     polynucleotide sequence except for the 3'-end thereof, which has at least one
     nucleotide analog that is incapable of hybridizing to a polynucleotide. Thus the
     use of 3'-etheno-dA-modified oligonucleotides both as inner primers in nested PCR
     greatly reduced the number of spurious amplification products as determined by gel
     electrophoresis. Kits for carrying out the above methods are also disclosed.
IC
     ICM C120001-68
     3-1 (Biochemical Genetics)
CC
ST
     polynucleotide amplification modified oligonucleotide primer;
     DNA amplification modified oligonucleotide primer; PCR modified
     oligonucleotide primer
     Nucleic acid amplification (method)
ΙT
        (DNA; method for polynucleotide amplification using modified
        oligonucleotide primers having a non-extendable 3'-end)
     Nucleic acid amplification (method)
ΙT
     PCR (polymerase chain reaction)
        (method for polynucleotide amplification using modified
        oligonucleotide primers having a non-extendable 3'-end)
     Primers (nucleic acid)
ΙT
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
        (method for polynucleotide amplification using modified
        oligonucleotide primers having a non-extendable 3'-end)
     PCR (polymerase chain reaction)
ΙT
        (nested; method for polynucleotide amplification using modified
        oligonucleotide primers having a non-extendable 3'-end)
     964-21-6D, 6-0-Methyl-2'-deoxyguanosine, oligonucleotide
ΙT
     3'-end modified
                      50591-13-4D, oligonucleotide 3'-end modified
     68498-25-9D, Ethenodeoxyadenosine, oligonucleotide 3'-end
                79393-91-2, 3',5'-Exonuclease
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
     (Uses)
        (method for polynucleotide amplification using modified
        oligonucleotide primers having a non-extendable 3'-end)
ΤТ
     964-21-6D, 6-0-Methyl-2'-deoxyguanosine, oligonucleotide
     3'-end modified
     RL: BUU (Biological use, unclassified); BIOL (Biological study); USES
        (method for polynucleotide amplification using modified
        oligonucleotide primers having a non-extendable 3'-end)
     964-21-6 HCAPLUS
RN
     Guanosine, 2'-deoxy-6-O-methyl- (CA INDEX NAME)
CN
```

AUTHOR(S):

Absolute stereochemistry.

OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD

(12 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1997:190264 HCAPLUS Full-text

DOCUMENT NUMBER: 126:293010

ORIGINAL REFERENCE NO.: 126:56737a,56740a

TITLE: The mechanism of decomposition of

N-methyl-N-nitrosourea (MNU) in water and a study of

its reactions with 2'-deoxyguanosine,

2'-deoxyguanosine 5'-monophosphate and d(GTGCAC) Golding, Bernard T.; Bleasdale, Christine; McGinnis,

Joseph; Mueller, Susanna; Rees, Hue Thu; Rees,

Nicholas H.; Farmer, Peter B.; Watson, William P.

CORPORATE SOURCE: Dep. Chem., Univ. Newcastle upon Tyne, Newcastle upon

Tyne, NE1 7RU, UK

SOURCE: Tetrahedron (1997), 53(11), 4063-4082

CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 126:293010

The carcinogenicity of N-methyl-N-nitrosourea (MNU) arises from its ability to AB methylate DNA. This occurs in an aqueous environment and therefore an appreciation of the mode of decomposition of MNU in water is essential to understanding the mechanism of DNA methylation and its base sequence dependence. The kinetics of MNU hydrolyses are shown to be first order in MNU with a steep rise in rate above pH 8. Using NMR for in situ monitoring of reaction intermediates and products from hydrolyzes of [13CO]MNU, [15NH2]MNU and [13CH3]MNU, it is proved that base-induced hydrolysis of MNU is initiated by deprotonation at the carbamoyl group. The critical reactive species are shown to be the methyldiazonium ion (Me-N2+) and cyanate (NCO-). Investigations of reactions of [13CH3]MNU with 2'-deoxyguanosine (dGuo) and 2'deoxyguanosine 5'-monophosphate (dGuo-5P) showed that: (a) the site of methylation of dGuo is highly pH-dependent (relatively more N-1 and O6-methylation compared to N-7 occurs at higher pH); (b) the principal site of methylation of dGuo-5P by MNU is at phosphate; (c) incorporation of deuterium into Me groups occurs in D2O at higher pH. Methylation of the oligonucleotide d(GT[15N]GCAC) by MNU in D2O showed partial deuteration of the N777-Me groups of the guanines, while methylation by MNU in water indicated no significant preference for either quanine with respect to N7methylation.

CC 22-8 (Physical Organic Chemistry)

Section cross-reference(s): 4, 6, 14, 26, 33

ST safety decompn mechanism aq methylnitrosourea; monophosphate deoxyguanosine aq methylnitrosourea; deoxyguanosine aq methylnitrosourea; oligonucleotide aq methylnitrosourea

IT Nucleosides, reactions

Oligonucleotides

RL: BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); RCT (Reactant); BIOL (Biological

study); PROC (Process); RACT (Reactant or reagent)

(decomposition mechanism of aqueous N-methyl-N-nitrosourea (MNU) and MNU's reactions with 2'-deoxyguanosine, 2'-deoxyguanosine 5'-monophosphate or d(GTGCAC))

IT 624-83-9P, Methyl isocyanate 964-21-6P 5132-79-6P

28074-91-1P

RL: PNU (Preparation, unclassified); PREP (Preparation) (decomposition mechanism of aqueous N-methyl-N-nitrosourea (MNU) and MNU's reactions with 2'-deoxyguanosine, 2'-deoxyguanosine 5'-monophosphate or d(GTGCAC))

IT 964-21-6P

RL: PNU (Preparation, unclassified); PREP (Preparation) (decomposition mechanism of aqueous N-methyl-N-nitrosourea (MNU) and MNU's reactions with 2'-deoxyguanosine, 2'-deoxyguanosine 5'-monophosphate or d(GTGCAC))

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS

RECORD (17 CITINGS)

REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1996:663725 HCAPLUS Full-text

DOCUMENT NUMBER: 126:72170

ORIGINAL REFERENCE NO.: 126:13909a,13912a

TITLE: MutS interaction with mismatch and alkylated base

containing DNA molecules detected by optical biosensor

AUTHOR(S): Babic, Ivan; Andrew, Susan E.; Jirik, Frank R.

CORPORATE SOURCE: Biomedical Research Center and Department of Medicine,

2222 Health Sciences Mall, University of British

Columbia, Vancouver, B.C., Can.

SOURCE: Mutation Research, Fundamental and Molecular

Mechanisms of Mutagenesis (1996), 372(1), 87-96

CODEN: MUREAV; ISSN: 0027-5107

PUBLISHER: Elsevier DOCUMENT TYPE: Journal LANGUAGE: English

AB An optical biosensor was used to monitor interactions between the Escherichia coli DNA mismatch repair mol. MutS and various immobilized oligonucleotides. While associating poorly with single-stranded DNA, MutS was capable of rapid association/dissociation from homoduplex DNA. The interaction of MutS with

oligonucleotide 30-mers containing single site mismatches demonstrated that during the dissociation phase, MutS binding was greatest to a G-G mismatch, followed by G-T>A-A>C-T, A-C. Binding to A-G, T-T and C-C mispairs was marginally higher than that seen between MutS and homoduplex DNA. The ability of MutS to interact with 30-mers containing alkylated bases was also tested. While binding to O6-methyl-G-C, or to O4-methyl-T-A base pairs was similar to that of homoduplex DNA, strong binding was seen to a O6-methyl-G-T mispair. O4-methyl-T-G, however, was poorly recognized by MutS, with relative binding affinity similar to homoduplex DNA, predicting poor in vivo recognition of O4-methyl-T-G by MutS. Interestingly, MutS demonstrated a relatively high affinity for an 1,N6-etheno-A-T containing homoduplex. Thus, in allowing rapid evaluation of interactions between such mols., the biosensor will be useful to structure-function analyses.

CC 9-5 (Biochemical Methods)

IT DNA

Oligonucleotides

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(MutS interaction with mismatch and alkylated base containing DNA mols.

detected by optical biosensor)

IT 964-21-6, 06-Methyldeoxyguanosine 50591-13-4 68498-25-9,

1,N6-Ethenodeoxyadenosine

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(MutS interaction with mismatch and alkylated base containing DNA mols. detected by optical biosensor)

IT 964-21-6, 06-Methyldeoxyguanosine

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(MutS interaction with mismatch and alkylated base containing DNA mols. detected by optical biosensor)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS

RECORD (22 CITINGS)

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1996:206593 HCAPLUS Full-text

DOCUMENT NUMBER: 125:11328

ORIGINAL REFERENCE NO.: 125:2485a,2488a

TITLE: N7-DNA: synthesis and base pairing of

oligonucleotides containing

 $N7-(2-\text{deoxy}-\beta-D-\text{erythro-pentofuranosyl})$  guanine

(N7Gd)

AUTHOR(S): Seela, Frank; Leonard, Peter

CORPORATE SOURCE: Inst. Chemie, Univ. Osnabrueck, Osnabrueck, D-49069,

Germany

SOURCE: Helvetica Chimica Acta (1996), 79(2), 477-87

CODEN: HCACAV; ISSN: 0018-019X

PUBLISHER: Verlag Helvetica Chimica Acta

DOCUMENT TYPE: Journal English LANGUAGE:

GΙ

The synthesis of oligonucleotides containing I (R = NH2, R1 = R2 = H) is described. AB The latter was prepared by nucleobase-anion glycosylation of 2-amino-6-methoxypurine with 2-deoxy-3,5-di-0-(4-toluoyl)- $\alpha$ -D- erythro-pentofuranosyl chloride followed by detoluoylation and displacement of the MeO group. Upon base protection with the Me2NHC:-residue the 4,4-dimethoxytrityl group was introduced at OH-C(5'). The phosphonate I [R = N:CNHMe2, R1 = CPh(4-C6H4OMe)2, R2 = PHO2-NHEt3+] and the phosphoramidite I [R = N:CNHMe2, R1 = CPh(4-C6H40Me)2, R2 = PN(CHMe2)2O(CH2)2CN]were prepared and used in solid-phase oligonucleotide synthesis. The selfcomplementary dodecamer d(N7G-C)6 shows sigmoidal melting. The Tm of the duplex is 40°. This demonstrates that quanine residues linked via N(7) of purine to the phosphodiester backbone are able to undergo base pairing with cytosine.

CC 33-9 (Carbohydrates)

ST oligonucleotide guanine deoxypentofuranosyl prepn base pairing; quanine deoxypentofuranosyl prepn

ΙT Nucleosides, preparation

> RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(deoxyribo-, purine, preparation and base pairing of

oligonucleotides containing (deoxypentofuranosyl)guanine)

ΤТ 4330-21-6 20535-83-5, 2-Amino-6-methoxypurine 67219-55-0

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation and base pairing of oligonucleotides containing (deoxypentofuranosyl) quanine)

159791-63-6P 177162-14-0P

177162-16-2P 177162-17-3P 177162-18-4P ΙT 177162-19-5P 177162-20-8P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation and base pairing of oligonucleotides containing (deoxypentofuranosyl)guanine)

ΙT 964-21-6P 177162-15-1P 177162-21-9P 177257-50-0P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and base pairing of oligonucleotides containing (deoxypentofuranosyl)guanine)

964-21-6P ΙT

> RL: SPN (Synthetic preparation); PREP (Preparation) (preparation and base pairing of oligonucleotides containing

(deoxypentofuranosyl)guanine)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS

RECORD (14 CITINGS)

L38 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1995:638582 HCAPLUS Full-text

DOCUMENT NUMBER: 123:83952

ORIGINAL REFERENCE NO.: 123:15045a,15048a

TITLE: 6-0-Substituted quanosine derivatives prepared by

acylation and substitution reactions

INVENTOR(S): Jones, Roger A.; Fathip, Reza; Gaffney, Barbara L.

PATENT ASSIGNEE(S): Rutgers, The State University, USA

SOURCE: U.S., 24 pp. Cont. of U.S. Ser. No. 439,616,

abandoned. CODEN: USXXAM

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND		DATE			
					-	
US 5412088	A	19950502	US	1992-863653		19920403
PRIORITY APPLN. INFO.:			US	1992-863653	В1	19920403
			US	1989-439616		19891120
OTHER SOURCE(S):	CASREA	CT 123:83952	; N	IARPAT 123:83952		

GΙ


AB The following species of N6-activated guanosine derivs. are disclosed: 2-Ntrifluoroacetamido-6-(4-nitrophenoxy)-9-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)purine (I), 2-N-trifluoroacetamido-6-pentafluorophenoxy-9- (2-deoxy- $\beta$ -D-erythropentofuranosyl) purine, and 2-amino-6-(4-dimethylaminopyridinium)-9-(2-deoxy- $\beta$ -Derythro- pentofuranosyl)purine. These quanosine compds. are useful as precursors in the synthesis of a wide variety of antiviral and anticancer nucleosides such as 2amino-2-deoxyadenosine or 6-thio-deoxyguanosine. Also disclosed are oligonucleotides containing the above nucleosides which are precursors to modified oligonucleotides which are useful as hybridization probes. Thus, e.g., 4 mmol deoxyguanosine was treated with 3.4 mL (24 mmol) of trifluoroacetic anhydride followed by 11.1 g (80 mmol) of 4-nitrophenol; workup afforded I in 67% yield. ICM C07H019-167 IC ICS C07H019-173; C07H019-20; C07H021-04 INCL 536027810 33-9 (Carbohydrates) CC 789-61-7P 964-21-6P ΙT 4546-70-7P 83024-94-6P 128790-73-8P 128790-75-0P 165290-73-3P 165290-74-4P 128790-74-9P 165290-75-5P 165337-47-3P 165337-46-2P 165337-48-4P RL: SPN (Synthetic preparation); PREP (Preparation) (6-O-substituted quanosine derivs. prepared by acylation and substitution reactions) 964-21-6P TT RL: SPN (Synthetic preparation); PREP (Preparation)

(6-O-substituted guanosine derivs. prepared by acylation and substitution reactions)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD

(4 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L38 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN 1995:51637 HCAPLUS Full-text ACCESSION NUMBER:

DOCUMENT NUMBER: 123:9832

123:2067a,2070a ORIGINAL REFERENCE NO.:

Synthesis of Oligodeoxyribonucleotides Containing TITLE: Analogs of O6-Methylguanine and Reaction with

O6-Alkylguanine-DNA Alkyltransferase Spratt, Thomas E.; Campbell, Colin R.

CORPORATE SOURCE: Division of Chemical Carcinogenesis, American Health

Foundation, Valhalla, NY, 10595, USA

Biochemistry (1994), 33(37), 11364-71 SOURCE:

CODEN: BICHAW; ISSN: 0006-2960

AUTHOR(S):

DOCUMENT TYPE: Journal LANGUAGE: English

O6-Alkylguanine-DNA alkyltransferase (AGT) repairs the mutagenic O6-methylguanine AB (O6mG) lesion by transferring a Me group from the 6-position of quanine to a cysteine residue on the protein. The simplest possible mechanism is an SN2 process in which the cysteine displaces the Me group off of the quanine in a concerted reaction. To probe the interactions between the protein and quanine leaving group, oligodeoxyribonucleotide duplexes containing analogs of O6mG were synthesized and then reacted with AGT. AGT was reacted with oligonucleotide duplexes of the sequence 5'-GGCGCTXGAGGCGTG-3' in which X was O6mG or an analog in which X was paired with C. All detected reactions were demethylations of the oligodeoxyribonucleotides except for O6-methyl-3-deoxyguanine, which reacted in an unknown manner. The second-order rate consts. obtained are reported. The large decreases in rate observed for changing the oxygen at the 6-position and the ring nitrogen at the 1-position suggest that these sites are hydrogen bond acceptors and/or proton acceptors during the reaction. The potential hydrogen bond from the protein to the 1-position of O6mG as well as the increase in rate observed for O6methylhypoxanthine suggests that the duplex opens up in order for the reaction to occur.

CC 33-9 (Carbohydrates)

Section cross-reference(s): 7, 22

IT Nucleotides, preparation

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(oligo-, deoxyribo-, synthesis of methylguanine analog-containing oligodeoxyribonucleotide duplexes and reaction with alkyltransferase)

IT 964-21-6P 23526-11-6P 37109-88-9P 37113-42-1P

duplexes and reaction with alkyltransferase)

52192-38-8P 86392-74-7P 115945-78-3P 163882-36-8P 163882-37-9P 163882-38-0P 163882-39-1P 163882-40-4P 163882-41-5P 163882-42-6P 163882-43-7P 163882-44-8P 163882-45-9P 163882-46-0P 163882-47-1P 163882-48-2P 163882-49-3P 163882-50-6P 163882-51-7P 163882-52-8P 163882-53-9P 163882-54-0P 163882-55-1P 163882-56-2P 163882-57-3P 163882-58-4P 163882-59-5P 163882-60-8P 163882-61-9P 163882-62-0P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(synthesis of methylguanine analog- containing oligodeoxyribonucleotide

IT 964-21-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(synthesis of methylguanine analog- containing oligodeoxyribonucleotide duplexes and reaction with alkyltransferase)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 32 THERE ARE 32 CAPLUS RECORDS THAT CITE THIS

RECORD (32 CITINGS)

L38 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1993:39313 HCAPLUS Full-text

DOCUMENT NUMBER: 118:39313

ORIGINAL REFERENCE NO.: 118:7183a,7186a

TITLE: 6-O-(Pentafluorophenyl)-2'-deoxyguanosine: a

versatile synthon for nucleoside and

oligonucleotide synthesis

AUTHOR(S): Gao, Hetian; Fathi, Reza; Gaffney, Barbara L.;

Goswami, Bhaswati; Kung, Pei Pei; Rhee, Youngsook;

Jin, Renzhe; Jones, Roger A.

CORPORATE SOURCE: Dep. Chem., Rutgers, State Univ. New Jersey,

Piscataway, NJ, 08855, USA

SOURCE: Journal of Organic Chemistry (1992), 57(25), 6954-9

CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 118:39313

GΙ

AB Title deoxyguanosine I can be used to generate in high yield 6-0-methyl-2'-deoxyguanosine, 2,6-diamino-9-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)purine, and related derivs. Further, after appropriate protection and derivatization, I can be incorporated into oligonucleotides and there used for postsynthetic oligonucleotide modification. This approach is particularly useful for preparation of oligonucleotides containing 2,6-diaminopurine residues or their 6-alkylamino derivs. In addition, reaction of I, or I-containing oligonucleotides, with 4- (dimethylamino)pyridine (DMAP) gives a fluorescent guanine-DMAP adduct.

CC 33-9 (Carbohydrates)

Section cross-reference(s): 41

IT Nucleotides, polymers

RL: SPN (Synthetic preparation); PREP (Preparation)

Τ

(oligo-, deoxyribo-, preparation and HPLC of)

IT 964-21-6P 4546-70-7P 145052-12-6P 145052-13-7P

 $145052 - 14 - 8P \qquad 145052 - 15 - 9P \qquad 145052 - 16 - 0P \qquad 145052 - 23 - 9P \qquad 145052 - 25 - 1P \qquad 145052 - 1P \qquad$ 

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)

IT 964-21-6P

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 28 THERE ARE 28 CAPLUS RECORDS THAT CITE THIS

RECORD (29 CITINGS)

L38 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1992:490686 HCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 117:90686

ORIGINAL REFERENCE NO.: 117:15849a,15852a

TITLE: Solid-phase synthesis of oligodeoxynucleotides

containing 6-0-alkylguanosines

AUTHOR(S): Roelen, H. C. P. F.; Brugghe, H. F.; Van den Elst, H.;

Klein, J. C.; Van der Marel, G. A.; Van Boom, J. H.

CORPORATE SOURCE: Gorlaeus Lab., Leiden, 2300 RA, Neth.

SOURCE: Recueil des Travaux Chimiques des Pays-Bas (1992),

111(5), 227-34

CODEN: RTCPA3; ISSN: 0165-0513

DOCUMENT TYPE: Journal LANGUAGE: English

AB High-quality oligodeoxynucleotides having an 6-O-alkyl-2'-deoxyguanosine (alkyl = Me, Et, Pr, n-hexyl) residue at a predetd. position were obtained via a solid-phase approach using the 2-cyanoethyl N,N-diisopropylphosphoramidites of 5'-O-(4,4'-dimethoxytrityl)-protected 6-O-alkyl-2'-deoxyguanosines having a free exocyclic amino group, and 5'-O-(4,4'-dimethoxytrityl) N-acyl-protected 2'-deoxynucleosides.

CC 33-9 (Carbohydrates)

IT Nucleotides, polymers

RL: RCT (Reactant); RACT (Reactant or reagent)

(oligo-, deoxyribo-, alkylguanosine-containing, solid-phase synthesis of)

IT 964-21-6P 50704-46-6P 142738-53-2P 142738-54-3P

142738-55-4P 142738-56-5P 142738-57-6P 142738-58-7P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and oligodeoxynucleotide synthesis with)

IT 964-21-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation and oligodeoxynucleotide synthesis with)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD

(1 CITINGS)

L38 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1991:673086 HCAPLUS Full-text

DOCUMENT NUMBER: 115:273086

ORIGINAL REFERENCE NO.: 115:46241a,46244a

TITLE: A sectored colony assay for monitoring mutagenesis by

specific carcinogen-DNA adducts in Escherichia coli

AUTHOR(S): Pauly, Gary T.; Hughes, Stephen H.; Moschel, Robert C. CORPORATE SOURCE: Frederick Cancer Res. Dev. Cent., Natl. Cancer Inst.,

Frederick, MD, 21702, USA

SOURCE: Biochemistry (1991), 30(50), 11700-6

CODEN: BICHAW; ISSN: 0006-2960

DOCUMENT TYPE: Journal LANGUAGE: English

AΒ To study the mutagenicity of various carcinogen-DNA adducts in E. coli, a cassette plasmid was developed that permits positioning of specific carcinogen-modified bases within the ATG initiation codon of the lacZ' lpha-complementation gene. Adduct-induced mutations inactivate the gene and lead to formation of blue and white sectored colonies when transformants from an  $\alpha$ -complementing version of E. coli strain AB1157 are grown on media containing 5-brown-4-chloro-3-indolyl  $\beta$ -D-galactoside. absence of mutation, blue colonies are produced. This system has been used to measure the mutagenicity of O6-methyl-, O6-ethyl-, and O6-butyl-2'-deoxyguanosine residues incorporated in place of the normal 2'-deoxyguanosine of the ATG initiation codon. Although a low percentage of sectored colonies was produced in this repairproficient strain, pretreatment of the bacteria with N-methyl-N'-nitro-Nnitrosoguanidine to disable DNA repair led to a dose-dependent increase in the percentage of sectored colonies. This percentage increased as a function of modified guanine in the order O6-benzyl- < O6-methyl- < O6-ethyl-2'-deoxyguanosine. The only mutations detected at the site of incorporation of these O6-substituted quanines were G-to-A transitions. This sectored colony assay system permits convenient screening of large nos. of colonies and simplifies quantification of modified base-induced mutations whether they be single-base changes, frameshifts, insertions, or deletions.

CC 4-6 (Toxicology)

IT Mutagens

(deoxyguanosine derivs. in oligonucleotides as, in

Escherichia coli)

IT Escherichia coli

(deoxyguanosine derivs. in oligonucleotides mutagenicity in)

IT Nucleotides, polymers

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)

(oligo-, mutagenicity of, in Escherichia coli)

T 961-07-9D, 2'-Deoxyguanosine, derivs. 964-21-6,

O6-Methyl-2'-deoxyguanosine 50704-46-6 129732-90-7

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (mutagenicity of, in Escherichia coli, DNA adducts in relation to)


IT 964-21-6, 06-Methyl-2'-deoxyguanosine

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (mutagenicity of, in Escherichia coli, DNA adducts in relation to)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS

RECORD (10 CITINGS)

L38 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1989:130229 HCAPLUS Full-text

DOCUMENT NUMBER: 110:130229

ORIGINAL REFERENCE NO.: 110:21387a,21390a

TITLE: Formation of O6-methyldeoxyguanosine at specific sites

in a synthetic oligonucleotide designed to

resemble a known mutagenic hotspot

AUTHOR(S): Richardson, Frank C.; Boucheron, Joyce A.; Skopek,

Thomas R.; Swenberg, James A.

CORPORATE SOURCE: Dep. Biochem. Toxicol., Chem. Ind. Inst. Toxicol.,

Research Triangle Park, NC, 27709, USA

SOURCE: Journal of Biological Chemistry (1989), 264(2), 838-41

CODEN: JBCHA3; ISSN: 0021-9258

DOCUMENT TYPE: Journal LANGUAGE: English

AΒ Four synthetic oligodeoxyribonucleotides of the sequence 5'-CCG1TG2G3G4ATATGGGCTG-3' were constructed with a 1',2'-[3H]deoxyguanosine located at one of the four sites indicated (1, 2, 3, or 4). This sequence was derived from a region of the Escherichia coli xanthine-guanine phosphoribosyltransferase gene where position 4 is a site frequently mutated by N-methyl-N'-nitrosourea as compared to sites 1-3. These four oligomers were alkylated in both single- and double-stranded form with Nmethyl-N'-nitrosourea, and the relative amount of O6-methyldeoxyguanosine (O6-MedGuo) formed at each position was quantitated. Up to a 5-6-fold greater formation of O6-MedGuo was observed at positions 3 and 4 as compared to positions 1 and 2. This uneven distribution was only observed in oligomers in the double-stranded form, suggesting that secondary structure was an important determinant in generating the uneven distribution of O6-MedGuo. Comparisons between the extent of O6-MedGuo formation and mutation frequency at the four positions suggest that a difference in the formation of promutagenic adducts at specific sites is just one of the factors involved in the generation of mutagenic hot-spots. The novel method developed was applied to the study of formation of O6-MedGuo at specific sites; however, it should be suitable for studying the formation and repair of DNA adducts generated by a variety of chems. in a wide variety of DNA sequences.

CC 4-6 (Toxicology)

Section cross-reference(s): 26

- ST methylnitrosourea methyldeoxyguanosine formation oligonucleotide
- IT Conformation and Conformers

Mutation

(methylnitrosourea methylation of oligonucleotides in

relation to)

IT Methylation

 $({\tt oligonucleotides},\ {\tt by\ methylnitrosourea},\ {\tt methyldeoxyguanosine}$ 

formation in relation to)

IT Nucleotides, polymers

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(oligo-, preparation and methylnitrosourea methylation of)

IT 578-76-7, N7-Methylguanine 964-21-6, O6-Methyldeoxyguanosine

20535-83-5, 06-Methylguanine

RL: FORM (Formation, nonpreparative)

(formation of, in oligonuclectide after methylnitrosourea

methylation)

IT 3040-49-1, N-Methyl-N'-nitrosourea

RL: RCT (Reactant); RACT (Reactant or reagent)

(oligonucleotide methylation by, methyldeoxyguanosine

formation in relation to)

IT 964-21-6, 06-Methyldeoxyguanosine

RL: FORM (Formation, nonpreparative)

(formation of, in oligonucleotide after methylnitrosourea

methylation)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-O-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS

RECORD (12 CITINGS)

L38 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 1982:85920 HCAPLUS Full-text

DOCUMENT NUMBER: 96:85920

ORIGINAL REFERENCE NO.: 96:14123a,14126a

TITLE: Synthesis and characterization of an

oligonucleotide containing a

carcinogen-modified base: O6-methylguanine

AUTHOR(S): Fowler, Kerry W.; Buechi, George; Essigmann, John M. CORPORATE SOURCE: Dep. Chem., Massachusetts Inst. Technol., Cambridge,

MA, 02139, USA

SOURCE: Journal of the American Chemical Society (1982),

104(4), 1050-4

CODEN: JACSAT; ISSN: 0002-7863

DOCUMENT TYPE: Journal LANGUAGE: English

AB The synthesis and characterization of the oligomer 5'-dTp(O3-Me)GpCpA-3' by the modified triester procedure is described, representing the preparation of a DNA fragment containing a base specifically covalently modified by a carcinogen. Using genetic engineering techniques, this tetramer will be substituted for a 5'-TpGpCpA-3' portion of the DNA of bacterial virus .vphi.X174 in order to study the effect on

replication of a well-characterized chemical modification of DNA at an exactly known point. The presence of O6-methylguanine in the oligomer inhibits the enzyme activities of snake venom phosphodiesterase and endonuclease P1.

CC 33-9 (Carbohydrates)

ST oligonucleotide carcinogen modified base; nucleotide oligo carcinogen modified base; methylquanine tetranucleotide

IT 964-21-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and benzoylation of)

IT 964-21-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and benzoylation of)

RN 964-21-6 HCAPLUS

CN Guanosine, 2'-deoxy-6-0-methyl- (CA INDEX NAME)

Absolute stereochemistry.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

## INVENTOR SEARCH

#### => FILE HCAPLUS

FILE 'HCAPLUS' ENTERED AT 17:33:56 ON 19 APR 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 19 Apr 2010 VOL 152 ISS 17

FILE LAST UPDATED: 18 Apr 2010 (20100418/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2010

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the first quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

#### => D STAT QUE L24

L21 592 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON HAYNES J?/AU
L22 225 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON ARRINGTON J?/AU
L24 4 SEA FILE=HCAPLUS SPE=ON ABB=ON PLU=ON L21 AND L22

=> D L24 IBIB ABS HITSTR 1-4

## L24 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:519843 HCAPLUS <u>Full-text</u>

DOCUMENT NUMBER: 145:416417

TITLE: Potent protective cellular immune responses generated

by a DNA vaccine encoding HSV-2 ICP27 and the E. coli

heat labile enterotoxin

AUTHOR(S): Haynes, Joel R.; Arrington, Joshua

; Dong, Lichun; Braun, Ralph P.; Payne, Lendon G.

CORPORATE SOURCE: PowderJect Vaccines Inc., Middleton, WI, USA

SOURCE: Vaccine (2006), 24(23), 5016-5026

CODEN: VACCDE; ISSN: 0264-410X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal LANGUAGE: English

AB A mouse model was employed to evaluate protective cellular immune responses induced

by an immediate early antigen of HSV-2. Particle-mediated DNA vaccination of mice with a DNA plasmid-encoding ICP27 resulted in the induction of ICP27-specific IFN- $\gamma$  and TNF- $\alpha$  production in Balb/c mice, but little protection to intranasal challenge with wild type HSV-2. However, when the DNA vaccine was supplemented with as little as 50 ng of a vector encoding the A and B subunits of the Escherichia coli heat labile enterotoxin (LT), animals were profoundly protected from morbidity and mortality. The ICP27 + LT-mediated protection was correlated with a large increase in ICP27-specific IFN- $\gamma$  and TNF- $\alpha$  production but cytokine-specific monoclonal antibody treatment at the time of challenge showed that protection was mediated predominantly by IFN- $\gamma$ . Furthermore, depletion of T cell subsets prior to infectious challenge demonstrated that removal of either CD8+ or CD4+ T cells impaired protection with CD8+ T cells appearing to play a direct effector role. These data demonstrate that augmented cellular immune responses resulting from LT vector plus antigen vector administration to the skin are biol. significant, leading to enhanced protection against mucosal pathogenic challenge. OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD

(6 CITINGS)

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2003:678494 HCAPLUS Full-text

DOCUMENT NUMBER: 139:212866

TITLE: Recombinant nucleic acids encoding bacterial

ADP-ribosylating exotoxin as adjuvant vectors for

vaccine delivery

INVENTOR(S): Haynes, Joel R.; Arrington, Joshua

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 72 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE		
				-			
US 20030162733	A1	20030828	US 2001-993307		20011126		
US 20060019921	A1	20060126	US 2005-179798		20050713		
PRIORITY APPLN. INFO.:			US 2000-253381P	P	20001127		
			US 2001-993307	В1	20011126		

AB Recombinant nucleic acid mols. are described. The mols. have two nucleic acid sequences, wherein the first nucleic acid sequence is a truncated A subunit coding region obtained or derived from a bacterial ADP-ribosylating exotoxin (CT-A), and the second nucleic acid sequence is a truncated B subunit coding region (CT-B). The bacterial ADP-ribosylating exotoxin is a cholera toxin or Escherichia coli heat labile enterotoxin. Vectors and compns. containing these mols. are also described. Methods for enhancing an immune response against an antigen of interest using these recombinant nucleic acid mols. and compns. are also described. Such adjuvant vectors encoding CT-A/CT-B and HBsAg or HIV-1 gp120 or HBsAg/HBcAg were prepared as vaccines with enhanced humoral and cellular immune responses.

L24 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2003:42130 HCAPLUS Full-text

DOCUMENT NUMBER: 138:105624

TITLE: Truncated genes for exotoxins for use as nucleic acid

adjuvants in vector vaccines

INVENTOR(S): Haynes, Joel R.; Arrington, Joshua

 $\mathbb{E}$  .

PATENT ASSIGNEE(S): Powderject Vaccines, Inc., USA

SOURCE: PCT Int. Appl., 143 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

	PATENT NO.				KIND DATE		APPLICATION NO.											
WO	2003004055				A2 20030116		WO 2001-US43151											
WO	WO 2003004055				A3 20031120													
	W:										, BG,							
		CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC.	, EE,	ES,	FI,	GB,	GD,	GE,	GH,	
		GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	, KG,	KP,	KR,	KΖ,	LC,	LK,	LR,	
		LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN	, MW,	MX,	${ m MZ}$ ,	NO,	NZ,	OM,	PH,	
		PL,	PT,	RO,	RU,	SD,	SE,	SG,	SI,	SK	, SL,	ΤJ,	TM,	TR,	TT,	TZ,	UA,	
		UG,	UZ,	VN,	YU,	ZA,	ZM,	ZW										
	RW:	GH,	GM,	KΕ,	LS,	MW,	MZ,	SD,	SL,	SZ	, TZ,	UG,	ZM,	ZW,	ΑM,	ΑZ,	BY,	
											CY,							
		GR,	ΙE,	ΙT,	LU,	MC,	NL,	PT,	SE,	TR	, BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	
		GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	ΤG								
CA	2429	708			A1		2003	0116		CA 2	2001-2429708					20011126		
AU	2001	2979	88		A1 2003012				AU 2001-297988						20011126			
AU	2001	2979	88		В2		2006	1026										
EP	1379	273			A2 20040114				EP 2001-274277						20011126			
EP	1379	273			В1		2009	0916										
	R:	ΑT,	BE,	CH,	DE,	DK,	ES,	FR,	GB,	GR,	, IT,	LI,	LU,	NL,	SE,	MC,	PT,	
		IE,	SI,	LT,	LV,	FΙ,	RO,	MK,	CY,	AL,	, TR							
CN	1537	013			Α		2004	1013	CN 2001-819570 20011							0011	126	
CN	1317	034			С		2007											
JP	2004	5361	07		T		2004	1202		JP 2	2003-	5100	65		2	0011	126	
JP	4221	289			В2		2009	0212										
	R 2001015646 A				2005	20051213 BR 2001-15646					20011126							
ΝZ	5261	75			Α		2006	0127		NZ 2	2001-526175			20011126				
ΑT	4428	58			T		2009	1015		AT 2	2001-274277			20011126				
PΤ	1379	273						1127										
ES	2332	261			Т3		20100201			ES 2	2001-274277			20011126				
IN	2003	CN00	798		A 2		20050415		IN 2003-CN798				2	0030	522			
IN	2291	52			A1		2009	0320										
MX	2003	0046	38		Α		2004	0420		MX 2	2003-	4638			2	0030	526	
ORIT	Y APP	LN.	INFO	.:						US 2	2000-	7243	15		A 2	0001	127	
											2001-					0011		
								_		_								

AB Vector vaccines including genes for ADP-ribosylating toxins that act as powerful adjuvants are described. The vector carries an antigen gene and the genes for a truncated A subunit derived from a bacterial ADP-ribosylating exotoxin, and the second nucleic acid sequence is a truncated B subunit coding region. The genes are expressible, but the gene products are not toxic. Toxicity is eliminated from the A subunits by deletion of the C-terminal KDEL or RDEL motif. Vectors and compns. containing these mols. are also described. Methods for enhancing an immune response against an antigen of interest using these recombinant nucleic acid mols. and compns. are also described. Adjuvant activity of cholera toxin and Escherichia coli heat-labile enterotoxin genes is demonstrated in mice.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2010 ACS on STN ACCESSION NUMBER: 2002:295134 HCAPLUS Full-text DOCUMENT NUMBER: 136:384628

TITLE: Plasmid vectors encoding cholera toxin or the

PUBLISHER:

heat-labile enterotoxin from Escherichia coli are

strong adjuvants for DNA vaccines

AUTHOR(S): Arrington, Joshua; Braun, Ralph P.; Dong,

Lichun; Fuller, Deborah H.; Macklin, Michael D.; Umlauf, Scott W.; Wagner, Sarah J.; Wu, Mary S.;

Payne, Lendon G.; Haynes, Joel R.

CORPORATE SOURCE: PowderJect Vaccines, Inc., Madison, WI, 53711, USA

SOURCE: Journal of Virology (2002), 76(9), 4536-4546

CODEN: JOVIAM; ISSN: 0022-538X American Society for Microbiology

DOCUMENT TYPE: Journal LANGUAGE: English

AB Two plasmid vectors encoding the A and B subunits of cholera toxin (CT) and two addnl. vectors encoding the A and B subunits of the Escherichia coli heat-labile enterotoxin (LT) were evaluated for their ability to serve as genetic adjuvants for particle-mediated DNA vaccines administered to the epidermis of laboratory animals. Both the CT and the LT vectors strongly augmented Th1 cytokine responses (gamma interferon [IFN- $\gamma$ ]) to multiple viral antigens when codelivered with DNA vaccines. In addition, Th2 cytokine responses (interleukin 4 [IL-4]) were also augmented by both sets of vectors, with the effects of the LT vectors on IL-4 responses being more antigen dependent. The activities of both sets of vectors on antibody responses were antigen dependent and ranged from no effect to sharp redns. in the IgG1-to-IgG2a ratios. Overall, the LT vectors exhibited stronger adjuvant effects in terms of T-cell responses than did the CT vectors, and this was correlated with the induction of greater levels of cAMP by the LT vectors following vector transfection into cultured cells. The adjuvant effects observed in vivo were due to the biol. effects of the encoded proteins and not due to CpG motifs

vectors following vector transfection into cultured cells. The adjuvant effects observed in vivo were due to the biol. effects of the encoded proteins and not due to CpG motifs in the bacterial genes. Interestingly, the individual LT A and B subunit vectors exhibited partial adjuvant activity that was strongly influenced by the presence or absence of signal peptide coding sequences directing the encoded subunit to either intracellular or extracellular locations. Particle-mediated delivery of either the CT or LT adjuvant vectors in rodents and domestic pigs was well tolerated, suggesting that bacterial toxin-based genetic adjuvants may be a safe and effective strategy to enhance the potency of both prophylactic and therapeutic DNA vaccines for the induction of strong cellular immunity.

OS.CITING REF COUNT: 44 THERE ARE 44 CAPLUS RECORDS THAT CITE THIS

RECORD (44 CITINGS)

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

#### SEARCH HISTORY

```
FILE 'HCAPLUS' ENTERED AT 17:01:55 ON 19 APR 2010
               E US2005-179798/APPS
              1 SEA SPE=ON ABB=ON PLU=ON US2005-179798/APPS
L1
                D SCAN
                SEL RN
     FILE 'REGISTRY' ENTERED AT 17:02:31 ON 19 APR 2010
             32 SEA SPE=ON ABB=ON PLU=ON (113516-56-6/BI OR 132328-28-0/BI
L2
                OR 139639-23-9/BI OR 147841-68-7/BI OR 155357-37-2/BI OR
                168417-72-9/BI OR 206906-04-9/BI OR 372487-09-7/BI OR 485815-63
                -2/BI OR 586482-03-3/BI OR 586485-90-7/BI OR 586485-91-8/BI OR
                586485-92-9/BI OR 586485-93-0/BI OR 586485-94-1/BI OR 586487-44
                -7/BI OR 586487-45-8/BI OR 586487-46-9/BI OR 586487-47-0/BI OR
                586487-48-1/BI OR 586487-49-2/BI OR 586487-50-5/BI OR 586487-51
               -6/BI OR 586487-52-7/BI OR 586487-53-8/BI OR 586487-54-9/BI OR
                586487-55-0/BI OR 586487-56-1/BI OR 586487-57-2/BI OR 586487-58
               -3/BI OR 586487-59-4/BI OR 7440-57-5/BI)
L3
               STRUCTURE UPLOADED
               D
             0 SEA SSS SAM L3
T. 4
L5
             0 SEA SSS FUL L3
            535 SEA SPE=ON ABB=ON PLU=ON C11H15N5O4/MF
L6
L7
             20 SEA SPE=ON ABB=ON PLU=ON L6 AND GUANOSINE/BI
                D SCAN
L8
                STRUCTURE UPLOADED
               D
             50 SEA SSS SAM L8
        67307 SEA SSS FUL L8
L10
L11
               STRUCTURE UPLOADED
L12
             50 SEA SUB=L10 SSS SAM L11
L13
               STRUCTURE UPLOADED
L14
              9 SEA SUB=L10 SSS SAM L13
               STRUCTURE UPLOADED
L15
               D
L16
              1 SEA SUB=L10 SSS SAM L15
               D SCAN
L17
             24 SEA SUB=L10 SSS FUL L15
               D SCAN
L18
             O SEA SPE=ON ABB=ON PLU=ON L2 AND L10
               D SCAN L2
               E O6-MEDG/CN
L19
             1 SEA SPE=ON ABB=ON PLU=ON "O6-METHYL-2'-DEOXYGUANOSINE"/CN
               D IDE CAN
    FILE 'HCAPLUS' ENTERED AT 17:25:39 ON 19 APR 2010
L20
             8 SEA SPE=ON ABB=ON PLU=ON L17
L21
            592 SEA SPE=ON ABB=ON PLU=ON HAYNES J?/AU
L22
            225 SEA SPE=ON ABB=ON PLU=ON ARRINGTON J?/AU
L23
             O SEA SPE=ON ABB=ON PLU=ON L20 AND (L21 OR L22)
             4 SEA SPE=ON ABB=ON PLU=ON L21 AND L22
L24
    FILE 'WPIX' ENTERED AT 17:27:37 ON 19 APR 2010
L25
            0 SEA SSS SAM L15
            0 SEA SSS FUL L15
L26
```

Serial#: 10/553,948 FILE 'BEILSTEIN' ENTERED AT 17:28:04 ON 19 APR 2010 L27 O SEA SPE=ON ABB=ON PLU=ON L17 L28 3 SEA SSS SAM L15 L29 24 SEA SSS FUL L15 L30 24 SEA SPE=ON ABB=ON PLU=ON L29 NOT L17 D STR L31 0 SEA SUB=L29 SSS SAM L3 L32 0 SEA SUB=L29 SSS FUL L3 FILE 'REGISTRY' ENTERED AT 17:33:28 ON 19 APR 2010 FILE 'HCAPLUS' ENTERED AT 17:33:32 ON 19 APR 2010 D STAT QUE L20 D L20 IBIB ABS HITSTR 1-8 FILE 'HCAPLUS' ENTERED AT 17:33:56 ON 19 APR 2010 D STAT QUE L24 D L24 IBIB ABS HITSTR 1-4 FILE 'REGISTRY' ENTERED AT 17:35:03 ON 19 APR 2010 D STAT QUE L19 D IDE CAN L19

FILE 'HCAPLUS' ENTERED AT 17:35:39 ON 19 APR 2010 L33 152 SEA SPE=ON ABB=ON PLU=ON L19 L34 33522 SEA SPE=ON ABB=ON PLU=ON IMMUNOSTIMULATION+PFT/CT OR IMMUNOSTIM?/BI L35 53933 SEA SPE=ON ABB=ON PLU=ON ANTISENS?/CT OR (ANTI(W)SENS? OR ANTISENS?)/BI L36 152611 SEA SPE=ON ABB=ON PLU=ON OLIGONUCLEOTIDES+OLD, NT, PFT/CT OR OLIGONUCLEO?/BI L37 18678 SEA SPE=ON ABB=ON PLU=ON (CPG? OR C(W)P(W)G?)/BI L38 18 SEA SPE=ON ABB=ON PLU=ON L33 AND ((L34 OR L35 OR L36 OR L37))

FILE 'HCAPLUS' ENTERED AT 17:44:35 ON 19 APR 2010 D STAT QUE L38 D L38 IBIB ABS HITIND HITSTR 1-18

=>

Uploading LL8.str

chain nodes : ring nodes : 1 2 3 4 5 6 7 8 9 10 11 12 13 14

chain bonds :
2-15 9-10
ring bonds :


 $1-2^{-}$  1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9 10-11 10-14 11-12 12-13 13-14

exact/norm bonds :

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:CLASS

Uploading LL15.str



chain nodes :
10 17 18 19

ring nodes :

 $1 \quad 2 \quad 3 \quad 4 \quad 5 \quad 6 \quad 7 \quad 8 \quad 9 \quad 11 \quad 12 \quad 13 \quad 14 \quad 15$ 

chain bonds :

2-17 4-10 9-11 10-19 17-18

ring bonds :

 $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 5-7 \quad 6-9 \quad 7-8 \quad 8-9 \quad 11-12 \quad 11-15 \quad 12-13 \quad 13-14 \quad 14-15$ 

exact/norm bonds :

G1:n-Bu, i-Bu, s-Bu, t-Bu

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 19:CLASS